छत्तीसगढ़ शासन
लोक स्वास्थ्य एवं परिवार कल्याण विभाग
::मंत्रालय::
महानदी भवन, नवा रायपुर अटल नगर-492002

क्रमांकGENS-2101/4186/2025-HEALTH SECTION-2 नवा रायपुर अटल नगर, दिनांक 12-11-2025

प्रति,

आयुक्त संचालक,
स्वास्थ्य सेवायें छत्तीसगढ़
संचालनालय स्वास्थ्य भवन,सेक्टर-19,
नार्थ ब्लाक, नवा रायपुर अटल नगर,
जिला-रायपुर (छ.ग.)।

विषयः- संचालनालय स्वास्थ्य सेवायें छ.ग. अंतर्गत 'Essential Drug List-2025' जारी किये जाने के संबंध में।
संदर्भः- आपका पत्र क्रमांक/DHS/16/के०स्टोर/2025/275 दिनांक 08.08.2025

--00--

उपरोक्त विषयांतर्गत संदर्भित पत्र का कृपया अवलोकन करने का कष्ट करें। जिसके अनुक्रम में प्रेषित 'Essential Drug List-2025' के IPHS तथा NHSRC के मापदंडों के आधार पर परीक्षण उपरांत छत्तीसगढ़ मेडिकल कार्पोरेशन लिमिटेड द्वारा की गई है अनुशंसा अनुसार संचालनालय स्वास्थ्य सेवायें छ.ग. अंतर्गत स्वास्थ्य संस्थाओं (जिला चिकित्सालय, सिविल अस्पताल, सामुदायिक स्वास्थ्य केन्द्र, प्राथमिक स्वास्थ्य केन्द्र, हेल्थ एंड वेलनेस सेंटर एवं उप स्वास्थ्य केन्द्रों) हेतु आवश्यक दवा की उपलब्धता सुनिश्चित किये जाने 'Essential Drug List-2025'को अधिसूचित किया जाता है।

संलग्नः- "Essential Drug List-2025'

Digitally signed by
DIVYA VAISHNAV
Date: 12-11-2025
12:18:01

(दिव्या वैष्णव)
अवर सचिव
छत्तीसगढ़ शासन
लोक स्वास्थ्य एवं परिवार कल्याण विभाग

पृ.क्रं GENS-2101/4186/2025-HEALTH SECTION-2 नवा रायपुर, अटल नगर, दिनांक 12-11-2025
प्रतिलिपिः-
1. विशेष सहायक, माननीय मंत्रीजी, स्वास्थ्य एवं परिवार कल्याण विभाग, मंत्रालय, महानदी भवन, नवा रायपुर अटल नगर, जिला-रायपुर, (छत्तीसगढ़)।
2. निज सचिव, सचिव, छत्तीसगढ़ शासन लोक स्वास्थ्य एवं परिवार कल्याण विभाग, मंत्रालय, महानदी भवन, नवा रायपुर अटल नगर, जिला-रायपुर, (छत्तीसगढ़)।
3. निज सचिव, सचिव छत्तीसगढ़ शासन, विभाग, मंत्रालय, महानदी भवन, नवा रायपुर अटल नगर, जिला-रायपुर, (छत्तीसगढ़)।
4. आयुक्त, संचालनालय चिकित्सा शिक्षा ,नार्थ ब्लाक, सेक्टर-19, नवा रायपुर, अटल नगर, जिला-रायपुर, (छत्तीसगढ़)।
5. मिशन संचालक, राष्ट्रीय स्वास्थ्य मिशन, छत्तीसगढ़, नार्थ ब्लाक, सेक्टर-19, नवा रायपुर, अटल नगर, जिला-रायपुर, (छत्तीसगढ़)।
6. नियंत्रक, खाद्य एवं औषधि प्रशासन ,कार्यालय इन्द्रावती भवन नवा रायपुर अटल नगर जिला-रायपुर छ.ग.।

---02

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 13/11/2025 04:16 pm

/2/

7. प्रबंध संचालक, छत्तीसगढ़ मेडिकल सर्विसेस कॉपेरिशन लिमिटेड, सेक्टर-27, नवा रायपुर अटल नगर, जिला-रायपुर, छ.ग.
की ओर सूचनार्थ एवं आवश्यक कार्यवाही हेतु प्रेषित।
8. स्टाक फाईल।

Digitally signed by
Jiwan Lal Netam
Date: 13-11-2025
15:45:27

अनुभाग अधिकारी
लोक स्वास्थ्य एवं परिवार कल्याण विभाग

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 13/11/2025 04:16 pm

ESSENTIAL DRUG LIST – 2025

Department of Health and Family Welfare, Government of Chhattisgarh

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

CONTENTS

Foreword 3
Secretary- Department of Health & Family Welfare and Medical Education 3
Commissioner and Director, Health Services cum Mission Director- National Health Mission 4
Background 5
Rationale and Approach for Revision of the Essential Drug List 8
Rationale for revision 8
Changing Disease Burden 9
Advances in Clinical Evidence and Treatment Guidelines 10
Strengthening Supply Chain Efficiency and Forecasting 10
Reducing Out-of-Pocket Expenditure and Advancing Health Equity 10
Rationalization and De-duplication Based on Facility Feedback 11
Approach to EDL revision 11
Essential Drug List as a Step Towards Universal Health Coverage 13
EDL as a Health system lever 13
EDL and Procurement Planning: The Bridge Between Policy and Access 13
Ensuring Access to Quality Medicines Across All Levels of Care 14
Equity and People-Centeredness Through the EDL 14
Rational Indenting and Responsible Use of the Essential Drug List 15
Conclusion 16
Annexure 1: EDL Technical Committee 18
Annexure 2: Essential Drug List- District Hospital 19
Annexure 3: Essential Drug List- Civil Hospital, Community Health Center and Urban Community Health Center 35
Annexure 4: Essential Drugs List Primary Health Center, Primary Health Center- AAM, and Urban Primary Health Center 47
Annexure 5: Essential Drug List- Sub-health Center- Ayushman Aarogya Mandir 53

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

FOREWORD

SECRETARY- DEPARTMENT OF HEALTH & FAMILY WELFARE AND MEDICAL EDUCATION



File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

COMMISSIONER AND DIRECTOR, HEALTH SERVICES CUM MISSION DIRECTOR- NATIONAL HEALTH MISSION



File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)

Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

BACKGROUND

Access to essential medicines is not merely a technical function of procurement but a **core determinant of public health equity and health system performance**. Medicines are among the most powerful tools available to improve health outcomes, prevent disease progression, and avert mortality. The concept of essential medicines, first introduced by the **World Health Organization (WHO) in 1977**, has since become a global standard to ensure that a limited number of cost-effective, evidence-based, and safe medicines are **available at all times, in appropriate dosage forms, and at prices individuals and communities can afford**.

WHO further recommends that the **Essential Medicines List (EML) be reviewed and revised every two years**, to reflect new clinical evidence, therapeutic advances, emerging disease patterns, and resistance trends. This biennial update cycle ensures that health systems remain responsive to evolving population health needs.

In line with this global framework, **Chhattisgarh developed its first comprehensive Essential Drug List (EDL) in 2021**, drawing upon:

- The **National List of Essential Medicines (NLEM)**,
- The **Indian Public Health Standards (IPHS)**, and
- The **WHO Model List of Essential Medicines**.

The EDL 2021 established a structured classification of drugs across the healthcare delivery spectrum—from Sub Health Centres (SHCs) to District Hospitals (DHs)—based on public health relevance and the facility's functional mandate. Key innovations included:

- **Color-coded categorization** (U: Universal, P: Primary, S: Secondary, T: Tertiary) enabling drug stratification as per service level,
- **Minimum buffer stock norms** for facilities and warehouses managed by CGMSCL,
- An integrated listing of **drugs and consumables** for streamlined forecasting and procurement,
- **District-specific antimalarial buffer norms** based on Annual Parasite Index (API), acknowledging epidemiological variations.

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

Year	Milestone
2000	Formation of Chhattisgarh as a separate state; initial focus on building basic healthcare infrastructure.
2003	Chhattisgarh became the **first state in India** to publish its own Essential Drug List (EDL).
2013	Developed a more **state-specific EDL** aligned with the National List of Essential Medicines (NLEM).
2016	Revised EDL to include drugs for **Non-Communicable Diseases (NCDs)** such as diabetes, hypertension, and cardiovascular conditions.
2019	Integrated with the **National Health Policy 2017** and updated to match the latest NLEM.
2021	EDL updated to incorporate **COVID-19 essential medicines** and revised to a total of **264 drugs**.
2024	Current revision underway to align with the **Essential Medicines List of the Centre**, reflect disease burden trends, and integrate digital supply chain tools (DPDMIS).

While EDL 2021 provided a strong foundation, the past three years have witnessed significant developments:

- **Shifts in disease burden**—notably the rising prevalence of non-communicable diseases (NCDs), mental health disorders, geriatric care needs, and persisting communicable disease challenges.
- **Expansion of Comprehensive Primary Health Care (CPHC)** under Ayushman Bharat, operationalized through Ayushman Aarogya Mandirs (AAMs).
- **Digitalization of the supply chain** via the Drug Procurement and Distribution Management Information System (DPDMIS), enabling real-time tracking and forecasting.
- Greater demand for **rationalization** of drug lists to align with **Standard Treatment Guidelines (STGs)** and avoid duplication or irrational fixed-dose combinations.

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

Moreover, the evidence suggests that irrational and outdated drug use leads to wastage, AMR, and poor clinical outcomes. In contrast, global experience shows that careful selection of a limited number of essential medicines improves prescribing practices, enhances treatment quality, and optimizes resource use

Recognizing these shifts and aligned with the WHO's two-year revision principle, the Department of Health and Family Welfare, Government of Chhattisgarh, initiated the 2024 revision of the Essential Drug List. The process has been technically anchored by the Directorate of Health Services (DHS), with support from a Technical Committee comprising public health experts, clinical specialists, procurement professionals, and program managers.

Key elements of the revision process include:

- **Consultations across all 33 districts** involving pharmacists, facility in-charges, and medical officers,
- Comparative **gap analysis** with updated NLEM and IPHS guidelines,
- Mapping against **prescription trends, consumption data, and epidemiological needs**,
- Emphasis on including drugs relevant to **emergency preparedness, maternal and child health, non-communicable diseases, mental health, and neglected tropical diseases**.

The **revised EDL – 2024**, presented in this compendium, is not merely a technical document. It is a **policy instrument and a public health enabler**—designed to:

- Standardize and rationalize therapeutic choices,
- Facilitate accurate demand forecasting,
- Improve efficiency and transparency in procurement,
- Promote access and equity in medicine availability, and
- Advance Chhattisgarh's progress towards **Universal Health Coverage (UHC)**.

This compendium reflects the state's **commitment to scientific rigor, stakeholder participation, and evidence-based planning**. It represents a critical step toward ensuring that **no citizen is denied access to quality-assured, affordable medicines** due to systemic gaps or outdated processes.

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

RATIONALE AND APPROACH FOR REVISION OF THE ESSENTIAL DRUG LIST

RATIONALE FOR REVISION

In addition to the overarching policy and technical motivations, the need for revising Chhattisgarh's Essential Drug List (EDL) is further underscored by **empirical evidence and programmatic learnings** drawn from state and national assessments. Field-level observations, comparative benchmarking against national standards, and facility performance reviews have highlighted **significant operational and structural gaps** in the current EDL (2021). These gaps impact service delivery, procurement planning, and medicine availability across various levels of care.

The following six critical observations form the immediate **technical and programmatic rationale** for undertaking a comprehensive revision of the EDL:

1. **Gaps in Drug Coverage Compared to IPHS/NHSRC EML 2022**: A comparative review with the IPHS/NHSRC Essential Medicine List (EML) 2022 revealed a lower number of formulations and drug molecules in Chhattisgarh's EDL 2021 at all level. The following table shows gaps in drug number and formulation in IPHS and State EDL

Facility	IPHS EDL	State EDL
DH	381	264
CHC	300	160
PHC	172	109
SHC/AAM	106	41

Additionally, state EDL 2025 is having difference in therapeutic area. For example, IPHS 2022 covers 33 therapeutic areas whereas state EDL 2025 is covering 29 therapeutic area.

2. Misalignment of Drug Packages Across Health Facility Categories: The state EDL-2019 lacks health facility-specific differentiation, especially for Sub-District Hospitals (SDH), CHCs, and Civil Hospitals. In state EDL-2019 there is no separate EDL has been defined for the SDH. In contrast, EML 2022 includes well-defined service packages mapped to each facility level. The absence of such differentiation in the state EDL leads to under-provisioning at higher levels of care.
3. Negative impact on State Ranking in central dashboard: Analysis of facility-level performance on the DVMS Dashboard indicates that the lack of comprehensive drug availability, driven by EDL limitations, has contributed to low rankings of public health facilities. Bridging these gaps is crucial to improving service coverage and utilization.

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

4. Policy Alignment with IPHS/NHSRC Guidelines and NHM Review Directives: The Ministry of Health and Family Welfare, Government of India, has advised states to align their EDLs with the IPHS/NHSRC EML 2022 to ensure policy uniformity and strengthen the Free Drugs Services Initiative under NHM. Additionally, the mid-term review of NHM programs has emphasized the need for EDL revision as a condition for performance-linked budgeting and compliance. Adhering to these directives is essential for securing central assistance and enhancing program effectiveness.
5. Drug Shortages at Primary-Level Facilities (AAM-SHCs and AAM-PHCs/UPHCs): Facility assessments have highlighted persistent gaps in medicine availability at Ayushman Aarogya Mandirs (AAMs), particularly at the Sub Health Centre (SHC) and Primary/Urban Primary Health Centre (PHC/UPHC) levels. These shortages stem from the absence of a well-defined and adequately populated list of essential medicines tailored to the specific service delivery needs of these facilities. To inch closer to the goals of Universal Health Coverage (UHC), the Government of India mandates the delivery of 12 comprehensive service packages at SHC-AAMs under the Ayushman Bharat initiative. However, the current EDL falls short of provisioning medicines aligned with these packages—particularly for non-communicable diseases (NCDs), mental health, geriatric care, and palliative care—thereby limiting the full operationalization of UHC services at the primary level. The revised EDL seeks to bridge this gap by mapping service package-linked essential medicines to SHC-AAM and PHC levels.

The Essential Drug List (EDL) functions as the backbone of a responsive and equitable health system. However, **its effectiveness depends on its ability to evolve with time**—incorporating new scientific evidence, adapting to population health needs, and responding to operational and regulatory developments. The 2024 revision of the Chhattisgarh EDL is thus underpinned by a confluence of **clinical, public health, operational, and policy imperatives**, detailed as follows:

CHANGING DISEASE BURDEN

India—and Chhattisgarh in particular—is undergoing a **rapid epidemiological transition**. While communicable diseases continue to pose challenges (e.g., tuberculosis, vector-borne diseases), the burden of **non-communicable diseases (NCDs)**—such as cardiovascular disease, diabetes, mental health disorders, and cancers—has surged. According to NFHS and SRS data, NCDs now contribute significantly to DALYs and out-of-pocket expenditure.

A revised EDL must reflect:

- Inclusion of **first-line and maintenance drugs for NCDs**

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

- **Psychotropic medications** in response to rising mental health morbidity
- Medicines for **geriatric, palliative, and rehabilitative care**, aligned with demographic shifts

ADVANCES IN CLINICAL EVIDENCE AND TREATMENT GUIDELINES

The **WHO Model List of Essential Medicines (2023)** and **NLEM (2022)** have incorporated new molecules with superior efficacy, safety, and pharmacoeconomic profiles. At the same time, many **irrational Fixed Dose Combinations (FDCs)** have been banned by CDSCO. Clinical protocols have also shifted with newer treatment algorithms, for instance:

- Single-pill combinations for hypertension,
- DOACs replacing warfarin in eligible patients,
- Inclusion of newer oral hypoglycemics like SGLT2 inhibitors in guidelines.

Updating the EDL ensures that **state protocols reflect current standard-of-care** and eliminate outdated, sub-therapeutic, or harmful options.

Major Bans (2016, 2018, 2019)

- **March 2016:** 344 FDCs banned
- **September 2018:** Ban reaffirmed for 328 of the earlier 344 FDCs
- **January 2019:** Additional 80 FDCs banned

STRENGTHENING SUPPLY CHAIN EFFICIENCY AND FORECASTING

The EDL is not only a clinical tool but also an essential lever for supply chain management and procurement planning. The growing complexity of health services under Comprehensive Primary Health Care (CPHC) and the operationalization of Ayushman Aarogya Mandirs (AAMs) necessitate:

- Accurate mapping of medicines to facility levels,
- Standardized demand generation through fixed-day indenting,
- Scientific forecasting and buffer stock management.

The revised EDL enables better integration with digital systems like DPDMIS, improving transparency, traceability, and timely replenishment.

REDUCING OUT-OF-POCKET EXPENDITURE AND ADVANCING HEALTH EQUITY

Out-of-pocket expenditure on medicines constitutes over **60–70% of household health spending** in low-income settings. Absence of essential medicines at government facilities often compels patients to procure from the private market, exposing them to high costs and potential substandard or counterfeit drugs.

A regularly updated EDL:

- Improves **availability of priority drugs** at public facilities,

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

- Strengthens **confidence in government health services**,
- Reduces catastrophic health expenditure,
- Directly supports the goal of **Universal Health Coverage (UHC)**.

RATIONALIZATION AND DE-DUPLICATION BASED ON FACILITY FEEDBACK

A systematic consultation across 33 districts revealed issues such as:

- Presence of **non-essential or rarely used drugs**,
- **Duplication across levels**, creating confusion and procurement inefficiencies,
- Exclusion of **commonly prescribed but essential drugs**: The revision exercise addressed these issues through a **ground-up, demand-driven approach** to ensure **clinical utility and operational relevance**.

APPROACH TO EDL REVISION

The 2024 EDL revision followed a **robust, consultative, and evidence-driven process** under the leadership of the **Directorate of Health Services (DHS)** and **National Health Mission (NHM), Chhattisgarh Medical Services Corporation Limited (CGMSCL)**, with technical guidance from a state-level **EDL Technical Committee**. The key steps were:

Step	Description
1. Technical Committee Formation	Multi-disciplinary team including clinicians, pharmacologists, health economists, supply chain experts, and program leads.
2. Policy and Literature Review	Alignment with WHO EML 2023, NLEM 2022, IPHS 2022, STGs, and CDSCO circulars.
3. District-Level Consultations	Facility-wise FGDs conducted at CMHO stores, DH, Civil Hospital, CHC, PHC-HWC in all 33 districts to gather ground-level insights.
4. Data Analytics	Consumption patterns, indent data, and warehouse inventory analyzed via DPDMIS to triangulate priorities.
5. Clinical Review	Review of therapeutic appropriateness, dosage forms, adverse event potential, and STG alignment.

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

6. Tier-Wise Stratification	Color-coded stratification (U/P/S/T) applied to ensure correct availability at different levels of care.
7. Buffer Stock Norms and Operational Notes	Final compendium includes buffer norms, indicative dosage, frequency, and warehousing considerations.
8. Final Validation and Approval	Technical Committee reviewed the draft for alignment with policy, programmatic, and operational needs.

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

ESSENTIAL DRUG LIST AS A STEP TOWARDS UNIVERSAL HEALTH COVERAGE

The Government of Chhattisgarh is committed to achieving the goal of **Universal Health Coverage (UHC)**, wherein every individual and community has access to quality healthcare services without suffering financial hardship. A foundational component of this vision is ensuring **equitable access to essential medicines**, which account for a significant proportion of out-of-pocket expenditure and are often the first point of contact between people and the health system.

An effectively designed and regularly updated **Essential Drug List (EDL)** is central to operationalizing UHC. It acts as a **technical, operational, and governance tool** that supports the availability, affordability, quality, and rational use of medicines across all levels of care. The revised EDL 2025 is a direct intervention to strengthen this commitment.

EDL AS A HEALTH SYSTEM LEVER

The Essential Drug List (EDL) is not merely a catalog of medicines; it is a strategic health systems instrument that integrates **clinical care**, **public procurement**, **financial protection**, and **governance**. By defining a limited list of **evidence-based, safe, cost-effective, and quality-assured medicines**, the EDL serves as a **gatekeeper** to ensure the right drugs reach the right patients at the right level of care.

In the context of **Universal Health Coverage (UHC)**—defined by WHO as ensuring "access to needed health services (including essential medicines) without financial hardship"—the EDL plays a **foundational role** across all three UHC dimensions:

- **Equity in access**: Medicines listed in the EDL are selected based on population health needs, especially for vulnerable, underserved, and high-burden groups.
- **Quality of care**: Ensures use of medicines that are clinically effective, aligned with standard treatment guidelines, and compliant with regulatory norms.
- **Financial protection**: Supports public procurement and free drug provisioning, reducing household out-of-pocket expenditures, which disproportionately stem from medicine costs.

In essence, the EDL operationalizes UHC from **policy to facility level**, translating health entitlements into tangible service delivery.

EDL AND PROCUREMENT PLANNING: THE BRIDGE BETWEEN POLICY AND ACCESS

Availability of medicines in public facilities is a **function of accurate demand forecasting, efficient procurement, and streamlined logistics**. The EDL acts as a **master reference document** for these operations:

- **Demand Forecasting:** The EDL enables facility-wise forecasting based on disease burden, seasonality, and consumption trends.
- **Procurement Planning:** CGMSCL will use the EDL to frame tender specifications, define packaging norms, and standardize dosage strengths. This improves transparency and cost competitiveness in public procurement.

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

- **Price Control and Vendor Management:** EDL-based planning allows leveraging pooled procurement and reference pricing to **reduce unit costs** and **ensure vendor accountability**.
- **Avoiding Stockouts and Overstocking:** By narrowing the procurement universe to rationally selected medicines, the EDL supports **optimal inventory control** and avoids wastage.

ENSURING ACCESS TO QUALITY MEDICINES ACROSS ALL LEVELS OF CARE

Chhattisgarh's health system architecture—from Ayushman Aarogya Mandirs (SHC-HWCs) to District Hospitals—requires a tiered yet consistent approach to drug availability. The EDL 2025 is **mapped to levels of care (Universal/Primary/Secondary/Tertiary)** using a **color-coded matrix**, ensuring:

- **Availability of critical drugs** where they are needed most.
- **Decentralized indenting and distribution** aligned with service delivery responsibilities.
- **Continuity of care**, ensuring that patients receive appropriate medicines at each referral point in the system.

This alignment strengthens service delivery under schemes like **Free Drugs Initiative**, **NCD Screening Program**, and **RMNCH+A strategy**, reducing out-of-pocket expenditure and dropout rates.

EQUITY AND PEOPLE-CENTEREDNESS THROUGH THE EDL

The EDL is an instrument of **social justice**. It prioritizes medicines that:

- Address the **burden of disease among the poor** and vulnerable.
- Are **not easily accessible or affordable** in the private sector.
- Treat **neglected diseases**, such as sickle cell disease and leprosy, prevalent in tribal and remote populations of Chhattisgarh.

Thus, EDL helps to **bridge the urban-rural and rich-poor divide** in access to medicines. The Essential Drug List is not merely a list—it is a **strategic enabler** of Universal Health Coverage. It links **clinical governance** with **supply chain efficiency**, **patient safety** with **public finance**, and **policy vision** with **grassroots service delivery**. The 2025 revision of the EDL marks a critical step in institutionalizing an **equity-driven, responsive, and quality-assured health system** in Chhattisgarh.

As the state moves forward on its UHC journey, the EDL will continue to serve as a **living document**, evolving in tandem with the needs of its people and the innovations in healthcare.

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

RATIONAL INDENTING AND RESPONSIBLE USE OF THE ESSENTIAL DRUG LIST

The revised Essential Drug List (EDL) of Chhattisgarh has been meticulously curated to align with national guidelines, including the National List of Essential Medicines (NLEM) and the Indian Public Health Standards (IPHS) 2022. It reflects a comprehensive and evidence-based approach to ensuring equitable access to quality-assured medicines across all tiers of public healthcare facilities.

However, the mere availability of a standardized EDL does not in itself guarantee optimal therapeutic outcomes. The utility and effectiveness of the EDL are contingent upon its **responsible and rational implementation at the point of use**, particularly during the annual indenting process undertaken by individual health facilities.

1. Indenting Must Be Guided by Consumption Patterns and Facility-Level Requirements

All healthcare facilities are hereby advised to base their indenting on **actual utilization data** and **disease burden trends**, rather than adopting uniform or indiscriminate ordering practices. Facilities must routinely analyze past consumption to assess demand more accurately.

Special attention must be paid to the following:

- Medicines which are **slow-moving or non-moving** in prior consumption cycles must be indented **judiciously**, with appropriate justification.
- Indenting should be **need-based**, not stock-driven, to avoid accumulation, expiration, and wastage of public resources.
- Facilities should adhere strictly to their **mandated scope of services** as per IPHS while raising indents.

2. Restriction on Indenting of High-End Medicines by Lower-Level Facilities

It is reiterated that **lower-level health facilities** (such as Sub-Health Centres and Primary Health Centres) **shall not indent high-end antibiotics, second-line antituberculars, higher antifungals, or other restricted-use drugs**, unless specifically authorized and clinically indicated.

These categories of medicines are to be:

- Reserved for **higher-level referral facilities** where appropriate diagnostic and clinical oversight is available.
- Governed by **therapeutic guidelines**, antimicrobial stewardship protocols, and procurement ceilings where applicable.
- Subject to additional scrutiny during the approval of indents to prevent irrational use and procurement inefficiencies.

3. Institutional Accountability and Role of Facility Personnel

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

All Medical Officers in charge and Pharmacists posted at public health facilities bear the responsibility of ensuring that indenting practices are aligned with the principles of **rational drug use**, **cost-efficiency**, and **public accountability**.

They are expected to:

- Review drug consumption data at regular intervals.
- Participate in capacity-building sessions on rational forecasting and indent planning.
- Avoid re-indenting medicines that have consistently remained underutilized without valid justification.
- Utilize the **Drug Procurement and Distribution Management Information System (DPDMIS)** or any other prescribed digital platform for data-driven indenting.

4. Oversight by District and State Authorities

Chief Medical and Health Officers (CMHOs), District Programme Management Units (DPMUs), , and State Drug Warehousing Units shall:

- Monitor indent patterns for compliance with EDL norms.
- Issue periodic directives to restrict or flag indents for non-essential or inappropriate medicines.
- Maintain a '**cautionary list**' of drugs subject to prior approval before procurement—particularly high-cost, low-utilization, or specialized therapeutic agents.
- Institutionalize a **review and feedback mechanism** to assess the appropriateness of facility-level indents before fulfillment.

5. Adoption of drugs and formulation as per program guideline: As the guidelines of national health programs and the list of recommended medicines evolve, the formulations included in the Essential Drug List (EDL) shall be updated and adopted accordingly.

CONCLUSION


The Essential Drug List (EDL) is a strategic tool that guides equitable access to essential medicines and enables evidence-based procurement planning. However, its effective implementation hinges on the **rational, need-based indenting** practices at the facility level. Facilities must ensure that their indents are grounded in past consumption data, aligned with their level-specific service delivery mandates, and avoid unnecessary procurement of specialized or underutilized medicines.

To institutionalize these practices, **revision of the EDL every three years is strongly recommended**, in accordance with global best practices and WHO's guidance on periodic updates to Essential Medicines Lists. This ensures that the EDL remains relevant to the evolving disease burden, therapeutic advancements, and programmatic priorities of the state.

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

Facilities and district authorities are expected to adhere strictly to the EDL framework and associated rational use principles. Non-compliance may warrant administrative scrutiny and corrective interventions. The Government of Chhattisgarh remains committed to strengthening its drug logistics and supply chain system, but this must be reinforced by **scientific stewardship, policy compliance, and accountability across all tiers of service delivery**.

ANNEXURE 1: EDL TECHNICAL COMMITTEE



संचालनालय स्वास्थ्य सेवायें
छत्तीसगढ़
स्वास्थ्य भवन,सेक्टर–19, नार्थ ब्लॉक,नवा रायपुर, अटल नगर
Email: centralstoredhs11@gmail.com

क्रमांक / DHS / 16 / के0स्टोर / 2025 / 213 नवा रायपुर अटल नगर, दिनांक 20.06.2025

// आदेश //

सचिव, छत्तीसगढ़ शासन, स्वास्थ्य एवं परिवार कल्याण विभाग से प्राप्त निर्देशानुसार, राष्ट्रीय आवश्यक औषधि सूची (NLEM)–2022 को ध्यान में रखते हुए, NHSRC द्वारा स्वास्थ्य संस्थावार बनाई गई आवश्यक दवाईयों की सूची (ESSENTIAL MEDICINES LIST)–2022, भारत सरकार अंतर्गत संचालित विभिन्न राष्ट्रीय कार्यक्रमों, विशेषज्ञों तथा सीजीएमएससी द्वारा प्राप्त अभिमत एवं सुझाव के आधार पर, छत्तीसगढ़ राज्य के स्वास्थ्य संस्थाओं हेतु संचालनालय, स्वास्थ्य सेवायें, छत्तीसगढ़ द्वारा जारी आवश्यक दवाईयों की सूची (EDL)–2021 में पुनर्संशोधन किया जाना है। इस हेतु आवश्यक दवाइयों की सूची का तुलनात्मक अध्ययन एवं परीक्षण कर, अभिमत प्रदाय करने हेतु संचालनालय स्तर पर तकनीकी समिति का गठन निम्नानुसार किया जाता है :–

1.	डॉ0 एस.के. पामभोई, प्रभारी संचालक, महामारी नियंत्रण	–अध्यक्ष
2.	डॉ0 डी.के. तुर्रे, उप संचालक, अस्पताल प्रशासन	–सदस्य
3.	डॉ0 खेमराज सोनवानी, उप संचालक, आई.डी.एस.पी. / एनएचएम	–सदस्य
4.	डॉ0 व्ही.आर. भगत, उप संचालक, शिशु स्वास्थ्य कार्यक्रम	–सदस्य
5.	डॉ0 उषा जोशी, प्रोफेसर, सिकल सेल संस्थान, चिकि.महावि. रायपुर	–विशेष आमंत्रित सदस्य
6.	डॉ0 धर्मेन्द्र गहवई, उप संचालक, केन्द्रीय भण्डार शाखा	–सदस्य सचिव
7.	डॉ0 शैलेन्द्र अग्रवाल, राज्य कार्यक्रम अधि0, मातृत्व स्वास्थ्य कार्यक्रम	–सदस्य
8.	डॉ0 अंकित शर्मा, मेडिसीन विशेषज्ञ, जिला चिकित्सालय, रायपुर	–सदस्य
9.	श्री हिरेन पटेल, महाप्रबंधक तकनीकी, सीजीएमएससी	–सदस्य
10.	डॉ0 अभ्युदय शक्ति तिवारी, ओ.एस.डी., एन.एच.एम.	–सदस्य
11.	डॉ0 मो. जावेद कुरैशी, योजना प्रबंधक, एन.एच.एम.	–सदस्य
12.	श्री अरूण लाल साहू, राज्य सलाहकार, प्रोक्यूरमेंट, एन.एच.एम.	–सदस्य

उक्त समिति 01 सप्ताह के भीतर प्रतिवेदन अधोहस्ताक्षरकर्ता को प्रस्तुत करेगी।

आयुक्त सह संचालक,
स्वास्थ्य सेवायें,
छत्तीसगढ़

पृ0क्रमांक / DHS / 16 / के0स्टोर / 2025 / नवा रायपुर अटल नगर, दिनांक .....

प्रतिलिपि :–

1. सचिव, छ0ग0 शासन, लोक स्वास्थ्य एवं परिवार कल्याण विभाग,
2. संचालक, चिकित्सा शिक्षा, सेक्टर–19, नवा रायपुर, अटल नगर,
3. मिशन संचालक, राष्ट्रीय स्वास्थ्य मिशन, छ0ग0, सेक्टर–19, नवा रायपुर, अटल नगर,
4. प्रबंध संचालक, सीजीएमएससी, छ0ग0, सेक्टर–27, नवा रायपुर, अटल नगर,
5. संचालक, स्वास्थ्य एवं परिवार कल्याण, सेक्टर–19, नवा रायपुर, अटल नगर,
6. सिविल सर्जन सह मुख्य अस्पताल अधीक्षक, जिला चिकित्सालय, रायपुर,
7. संबंधित अधिकारी.....

की ओर सूचनार्थ एवं कार्यवाही हेतु प्रेषित है।

8. स्टेट टेक्नीकल अधिकारी, पाथ, छ0ग0 की ओर सूचनार्थ एवं आवश्यक सहयोग हेतु प्रेषित।
9. आदेश नस्ती।

आयुक्त सह संचालक,
स्वास्थ्य सेवायें,
छत्तीसगढ़

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

ANNEXURE 2: ESSENTIAL DRUG LIST- DISTRICT HOSPITAL

List of Essential Medicine Recommended for District Hospital

S. No.	Medicine Name
	Anesthetic Agents
1	Halothane Gas for Inhalation (Protect from light and store at temperature not exceeding 25°C)
2	Isoflurane Gas for Inhalation
3	Ketamine Injection 10 mg/ml 1 Ketamine Injection 50 mg/ml
4	Nitrous Oxide Gas for Inhalation (Store under pressure in metal cylinders of the type conforming to the appropriate safety regulations and at temperature not exceeding 370C)
5	Oxygen Gas for Inhalation
6	Propofal Injection 10 mg/ml 2 (Should not be allowed to freeze)
7	Sevoflurane Injection
8	Promethazine* Injection 25 mg/ml, 50 mg/ml 3
9	Pentazocine Injection 30mg/ml 4 (Protect from light & moisture)
10	Thiopentane Injection 0.5 gm/1 gm 2
11	Bupivacaine Injection 0.5 mg/ml (sensorcain)
12	Lignocaine* Injection 2% Lignocaine Injection 4%w/v, 5%w/v Lignocaine Jelly Lignocaine Ointment 2%-5% Lignocaine Spray 10%
13	Lignocaine (A) + Adrenaline (B) Injection 1% (A) + 1:200000 (5 mcg/ml) (B) Injection 2% (A) + 1:200000 (5 mcg/ml) (B)
14	Atropine* Injection 0.6 mg/ml, 1 mg/ml (Protect from light)
15	Glycopyrolate Injection 0.2 mg/ml
16	Midazolam* Injection 1 mg/ml 2,4 Midazolam Tablet 250 mg Midazolam Tablet 500 mg
	Non-opioid Analgesic, Anti-Pyretic and Nonsteroidal Anti-Inflammatory Medicines
17	Diclofenac Tablet 50 mg Diclofenac Injection 25 mg/ml Diclofenac Injection 25 mg/3 ml Diclofenac Gel 1%W/W
18	Ibuprofen* Tablet 200 mg Ibuprofen Tablet 400 mg Ibuprofen Syrup 100 mg/5 ml
19	Paracetamol* Tablet 500 mg Paracetamol Tablet 650 mg Paracetamol Injection 150 mg/ml Paracetamol Suppository 80 mg Paracetamol Syrup 125 mg/5 ml
20	Colchicine Tablet 0.5 mg (Protect from light)

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

21	Azathioprine* Tablet 50 mg 2
22	Hydroxychloroquine Tablet 200 mg Hydroxychloroquine Tablet 400 mg
23	Methotrexate* Tablet 2.5 mg2 (Tablet: Protect from light and moisture) Methotrexate Tablet 7.5 mg Methotrexate Injection 50 mg/ml (Injection: Protect from light)
24	Sulfasalazine Tablet 500 mg
25	Naproxen Tablet 250 mg Naproxen Tablet 500 mg
26	Duloxetine Tablet 10 mg, 30 mg, 60 mg
27	Tapentadol Tablet 25 mg, 100 mg
28	Gabapentin Tablet 100 mg, 400 mg
29	Pregabalin Tablet 25 mg,150 mg Pregabalin syrup 50 mg/ml
30	Nortriptyline Tablet 10 mg, 50 mg
	Anti-Allergic and Medicines used in Anaphylaxis
31	Adrenaline Injection 1 mg/ml (1:1000) (Protect from light, preferably in containers filled with nitrogen)
32	Cetirizine Tablet 5 mg Cetirizine Tablet 10 mg Cetirizine Oral Liquid 5 mg/5 ml
33	Chlorpheniramine Tablet 4 mg 3 Chlorpheniramine Oral Liquid 2 mg/5 ml
34	Dexamethasone* Tablet 0.5 mg Dexamethasone Injection 4 mg/ml (Protect from light and store at temperature not exceeding 300C)
35	Hydroxyzine Syrup 10 mg/5 ml Hydroxyzine Tablet 25 mg
36	Hydrocortisone* Powder for Injection 100 mg Hydrocortisone Injection 200 mg Hydrocortisone Cream/Gel/Ointment 0.5%/1%
37	Pheniramine Maleate Injection 22.75 mg/ml3
	Antidote and other Substances used in Poisoning
38	Activated Charcoal (Protect from moisture)
39	Calcium Gluconate* Injection 100 mg/ml Calcium Gluconate Injection 1 gm, IV-10 ml amp
40	Desferrioxamine Injection 500 mg (Protect from light and store in refrigerator (2-80C). Do not freeze)
41	N-acetylcysteine Injection 200 mg/ml N-acetylcysteine Sachet 200 mg N-acetylcysteine Tablet 600 mg/Dispersible
42	Naloxone Injection 0.4 mg/ml 5
43	Neostigmine* Injection 0.5 mg/ml
44	Snake Venom Antiserum Injection a) Soluble/Liquid Polyvalent b) Lyophilized Polyvalent
45	Deferiprone Capsule 250mg & 500mg
46	Deferasirox Tablet 250mg & 500mg
	Anti-Convulsant/Anti-Epileptic Medicines

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

47	Carbamazepine* Tablet 100 mg, 200 mg Carbamazepine Oral Liquid 100 mg/5 ml Carbamazepine CR Tablet 200 mg, 400 mg
48	Levetiracetam Tablet 250 mg, 500 mg
49	Lorazepam Tablet 1 mg 5 Lorazepam Injection 1 mg/ml Lorazepam Injection 2 mg/ml
50	Magnesium Sulphate Injection 500 mg/ml Magnesium Sulphate Injection IP 50% w/v
51	Phenytoin Tablet 50 mg/100 mg, 300 mg Phenytoin Oral Liquid 30 mg/5 ml Phenytoin Oral Liquid 125 mg/5 ml Phenytoin Injection 25 mg/ml, 50 mg/ml Phenytoin ER Tablet 300 mg
52	Sodium Valproate Tablet 100 mg Sodium Valproate Tablet 500 mg Sodium Valproate Oral Liquid 200 mg/5 ml
	Anti-Infective Medicines
53	Albendazole Tablet 400 mg Albendazole Oral Liquid 200 mg/5 ml
54	Diethylcarbamazine Tablet 100 mg Diethylcarbamazine Oral Liquid 120 mg/5 ml (Protect from moisture)
55	Ivermectin Tablet 6mg
56	Amoxicillin Capsule 250 mg Amoxicillin Tablet 500 mg Amoxicillin Suspension 125 mg/5 ml Amoxicillin Oral Liquid 250 mg/5 ml (Capsule, oral suspension: Store protected from moisture and light at a temperature not exceeding 300C)
57	Ampicillin Capsule 500 mg Ampicillin Injection 500 mg/ml
58	Amoxicillin (500 mg) + Clavulanic Acid (125 mg) Tablet Amoxicillin (875 mg) + Clavulanic Acid (125 mg) Tablet Amoxicillin (500 mg) + Clavulanic Acid (100 mg) Injection Amoxicillin (1 gm) + Clavulanic Acid (200 mg) Injection Amoxicillin (125 mg) + Clavulanic Acid (31.25 mg/5 ml) Dry Syrup
59	Tablet Penicillin V (Phenoxymethyl Penicillin) 250 mg
60	Benzylpenicillin Injection 10 lakh unit Benzathine Benzylpenicillin Injection 12 lakh unit
61	Cefazolin Powder for Injection 500 mg Cefazolin Powder for Injection 1 gm (The constituted solution should be stored protected from light and used within 24 hours when stored at a temperature not exceeding 300C or within 4 days when stored between 2 to 80C)
62	Cefixime Tablet 200 mg 4 Cefixime Oral Liquid 50 mg/5 ml
63	Cefotaxime Injection 1 g/vial Powder for Injection 250 mg
64	Ceftazidime Powder for Injection 250 mg4 Ceftazidime Powder for Injection 1g (Store in sterile containers sealed, so as to exclude micro-organisms protected from moisture at a temperature not exceeding 300C)
65	Ceftriaxone Powder for Injection 250 mg4 Ceftriaxone Powder for Injection 500 mg Ceftriaxone Powder for Injection 1 g
66	Cloxacillin Capsule 250 mg Cloxacillin Oral Liquid 125 mg/5 ml Cloxacillin Injection 500 mg/vial
67	Piperacillin (A) + Tazobactam (B) Powder for Injection 1 g (A) + 125 mg (B) Powder for Injection 2 g (A) + 250 mg (B) Powder for Injection 4 g (A) + 500 mg (B) (Store below 250C)

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

68	Azithromycin Tablet 250 mg Azithromycin Tablet 500 mg Azithromycin Oral Liquid 200 mg/5 ml
69	Norfloxacin Dispersible Tablet 100 mg Norfloxacin Tablet 400 mg
70	Ciprofloxacin Tablet 250 mg Ciprofloxacin Tablet 500 mg Ciprofloxacin Oral Liquid 250 mg/5 ml Ciprofloxacin I.V 200 mg/100 ml
71	Clarithromycin Tablet 250 mg Clarithromycin Tablet 500 mg Clarithromycin Oral Liquid 125 mg/5 ml
72	Co-trimoxazole* (Protect from light and moisture) [Sulphamethoxazol e (A) +Trimethoprim (B)] Tablet 400 mg (A) + 80 mg (B) Tablet 800 mg (A) + 160 mg (B) Oral liquid 200 mg (A) + 40 mg (B)/5 ml (Suspension should not be allowed to freeze)
73	Doxycycline Capsule 100 mg Doxycycline Dry Syrup 50 mg/5 ml
74	Metronidazole* Tablet 200 mg, 400 mg (Store protected from light and moisture) Metronidazole Injection 5 mg/ml, 500 mg/100 ml Metronidazole Oral Liquid 200 mg/5 ml (Store injection in a single dose container)
75	Nitrofurantoin Tablet 100 mg Nitrofurantoin Oral Liquid 25 mg/5 ml
76	Vancomycin Powder for Injection 250 mg Vancomycin Powder for Injection 500 mg Vancomycin Powder for Injection 1 g (Store in an air tight container protected from light)
77	Amikacin Injection 100 mg2 Amikacin Injection 500 mg
78	Clofazimine Tablet 50 mg 4 Clofazimine Capsule 100 mg Clofazimine Capsule 200 mg
79	Delamanid Tablet 50 mg
80	Dapsone Tablet 25 mg Dapsone Tablet 100 mg
81	Rifampicin* Tablet 75 mg4 Rifampicin Capsule 150 mg Rifampicin Capsule 300 mg Rifampicin Capsule 450 mg Rifampicin Oral Liquid 100 mg/5 ml
82	Capreomycin Injection 1 gm4 Capreomycin Injection 750 mg Capreomycin Injection 500 mg
83	Cycloserine Capsule 125 mg4 Cycloserine Capsule 250 mg
84	Ethambutol Tablet 100 mg4 Ethambutol Tablet 200 mg Ethambutol Tablet 600 mg
85	Ethionamide Tablet 125 mg4 Ethionamide Tablet 250 mg
86	Isoniazid Tablet 50 mg4 Isoniazid Tablet 75 mg Isoniazid Tablet 100 mg Isoniazid Tablet 300 mg Isoniazid Oral Liquid 100 mg/5 ml
87	Kanamycin Powder for Injection 500 mg2 Kanamycin Powder for Injection 750 mg Kanamycin Powder for Injection 1 g
88	Levofloxacin Tablet 250 m g4 Levofloxacin Tablet 500 mg, Levofloxacin Tablet 750 mg
89	Linezolid Tablet 600 mg

90	Moxifloxacin Tablet 500 mg4 Moxifloxacin Tablet 400 mg
91	Sodium Aminosalicylate Granules 10 gm4 Sodium Aminosalicylate Granules 9.2 gm
92	Pyrazinamide Tablet 150 mg4 Pyrazinamide Tablet 400 mg Pyrazinamide Tablet 500 mg Pyrazinamide Tablet 750 mg Pyrazinamide Oral Liquid 250 mg/5 ml
93	Rifabutin* Capsule 150 mg4 Rifabutin Injection 500 mg
94	Streptomycin Powder for Injection 750 mg2 Streptomycin Powder for Injection 1 gm Streptomycin Powder for Injection 500 gm
95	Bedaquiline Tablet 100 mg
96	Amphotericin B* Injection 50 mg2 a) Amphotericin B (conventional) b) Amphotericin B (Lipid)
97	Clotrimazole Tablet 100 mg Clotrimazole Pessary 100 mg (Do not crush pessaries)
98	Fluconazole Tablet 150 mg (Store in an airtight container)
99	Itraconazole Tablet/Capsule 100 mg
100	Acyclovir Tablet 200 mg (Store tablets protected from light) (Acyclovir Injection 250 mg For infusion: Store protected from moisture in a sterile tamper evident container sealed so as to exclude micro-organisms at a temperature not exceeding 300C)
101	Ganciclovir Capsule 200 mg
102	Abacavir Tablet 300 mg
103	Lamivudine (A) + Zidovudine (B) Tablet 150 mg (A) + 300 mg (B) (Store protected from moisture)
104	Tenofovir (A) + Lamivudine (B) + Efavirenz (C) Tablet 300 mg (A) + 300 mg (B) + 600 mg (C)
105	Zidovudine Tablet 300 mg Zidovudine Oral liquid 50 mg/5 ml
106	Zidovudine (A) + Lamivudine (B) + Nevirapine(C) Tablet 300 mg (A) + 150 mg (B) + 200 mg (C)
107	Efavirenz Tablet 50 mg Efavirenz Tablet 200 mg Efavirenz Tablet 600 mg
108	Nevirapine Dispersible Tablet 50 mg Nevirapine Dispersible Tablet 200 mg (Protect from light and moisture and store at temperature not exceeding 300C)
109	Lopinavir (A) + Ritonavir (B) (Tablet: Protect from moisture and store at temperature not exceeding 300C) Capsule Lopinavir 133 mg + Ritiovir 33 mg Tablet Lopinavir 200 mg +Ritinovir 50 mg (Capsule: Store protected from moisture in refrigerator (2 to 80C))
110	Ritonavir Tablet 100 mg
111	Entecavir Tablet 0.5 mg Entecavir Tablet 1 mg
112	Sofosbuvir Tablet 400 mg
113	Tenofovir Tablet 300 mg Tenovir Aalafenamide Fumarate Tablet 25 mg Tenofovir Disoproxil* Fumarate Tablet 300 mg

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

114	Sofosbuvir 400 mg + Velpatasvir 400 mg Tablet
115	Diloxanide Furoate Tablet 500 mg
116	Tinidazole Tablet 300 mg, 500 mg
117	Miltefosine Capsule 10 mg Miltefosine Capsule 50 mg (Store in a cool place, protected from light and moisture)
118	Tablet Artemether (A) [As per NVBDC program guideline by GoI]+ Lumefantrine (B) Tablet 20 mg (A) + 120 mg (B) Tablet 80 mg (A) + 480 mg (B) Oral liquid 80 mg (A) + 480 mg (B)/5 ml
119	Artesunate Powder for Injection 60 mg [As per NVBDC program guideline by GoI] Artesunate Powder for Injection 120 mg [As per NVBDC program guideline by GoI]
120	Artesunate (A) + Sulphadoxine - Pyrimethamine (B) combi pack (A+B) ACT- SP less than 1 year-Pink Color: 3 Tablet 25 mg (A) + 1 Tablet (250 mg + 12.5 mg)(B) ACT -SP (2-4 years) Yellow Color: 3 Tablet 50 mg (A) + 1 Tablet (500 mg + 25 mg) (B) ACT- SP (5-8 years) Green Color: 3 Tablet 100 mg (A) + 1 Tablet (750 mg + 37.5 mg) ACT- SP (9-14 years) Red Color: 3 Tablet 150 mg (A) + 2 Tablet (500 mg + 25 mg) ACT- SP (Adult/Above 15 Years) White Color 3 Tablet 200 mg (A) + 2 Tablet (750 mg + 37.5 mg) (B) OR 3 Tablet (500 mg + 25 mg) (B) [As per NVBDC program guideline by GoI]
121	Chloroquine Tablet 150 mg [As per NVBDC program guideline by GoI] Chloroquine Oral Liquid 50 mg/5 ml
122	Clindamycin Capsule 150 mg Clindamycin Capsule 300 mg (Protect from moisture)
123	Primaquine Tablet 2.5 mg Primaquine Tablet 7.5 mg Primaquine Tablet 15 mg (Protect from moisture) [As per NVBDC program guideline by GoI]
124	Quinine Tablet 300 mg, [As per NVBDC program guideline by GoI] Quinine Injection 300 mg/ml (Protected from light) [As per NVBDC program guideline by GoI]
	Anti- covid medicines
125	Favipiravir Tablet 200 mg, 400 mg
126	Remdesivir Injection 100 mg/20 ml
	Anti-Migraine Medicines
127	Sumatriptan Tablet 25 mg
128	Flunarizine Tablet 5 mg Flunarizine Tablet 10 mg
129	Propranolol Tablet 5 mg, 10 mg, 40 mg
	Anti-Neoplastic Medicines
130	5-Fluorouracil Injection 250 mg/5 ml (Protect from light in a single dose container and store at temperature not exceeding 300C) (Injection should not be allowed to freeze) As per national program guideline
131	Actinomycin D Injection 0.5 mg (5 mcg)
132	All-Trans Retinoic Acid Capsule 10 mg
133	Arsenic Trioxide Injection 1 mg/ml
134	Bleomycin Powder for Injection 15 units3
135	Calcium Folinate Tablet 15 mg Calcium Folinate Injection 3 mg/ml
136	Capecitabine Tablet 500 mg
137	Carboplatin Injection 10 mg/ml
138	Chlorambucil Tablet 2 mg/5 mg3 Chlorambucil Powder for Injection 500 mg

139	Cyclophosphamide Powder for Injection 500 mg 3 (Store in refrigerator (2 to 80C). Avoid long exposure to temperature above 300C)
140	Docetaxel Powder for Injection 20 mg
141	Etoposide Capsule 50 mg2 Etoposide Capsule 100 mg (Capsules should not be stored in refrigerator)
142	Imatinib Tablet 100 mg Imatinib Tablet 400 mg
143	Paclitaxel Injection 30 mg/5 ml Paclitaxel Injection 100 mg/16.7 ml
144	Trastuzumab Injection 440 mg/50 ml
	Hormones and Anti-Hormonal Medicines used in Cancer Therapy
145	Bicalutamide Tablet 50 mg
146	Prednisolone* Tablet 5 mg Prednisolone Tablet 10 mg Prednisolone Oral Liquid 5 mg/5 ml Prednisolone Oral Liquid 15 mg/5 ml (Protect from light and store at temperature not exceeding 300C)
147	Letrozole Tablet 2.5 mg
148	Tamoxifen Tablet 10 mg Tamoxifen Tablet 20 mg Injection Tamoxifen 20 mg
	Immunosuppressive Medicines
149	Mycophenolate Mofetil Tablet 250 mg
150	Cyclosporine Capsule 10 mg, 25 mg, 50 mg, 100 mg, Oral Liquid 100 mg/ml Injection 50 mg/ml
151	Tacrolimus Capsule 0.5 mg, 1 mg, 2 mg
	Pain and Palliative Care Medicines
152	Allopurinol* Tablet 100 mg, 300 mg
153	Acetylsalicylic Acid (Aspirin)* Tablet 25 mg Acetylsalicylic Acid Tablet 50 mg Acetylsalicylic Acid Tablet 75 mg Acetylsalicylic Acid Tablet 150 mg, 300 mg
154	Amitriptyline* Tablet 10 mg/25 mg
155	Diazepam* Injection 5 mg/ml5 (Injection: Store in single dose or multi dose container protected from light) Diazepam Oral Liquid 2 mg/5 ml Diazepam Suppository 5 mg Diazepam Injection 5 mg/ml Diazepam Tablet 5 mg Diazepam Injection 10 mg/2 ml
156	Filgrastim Injection 300mcg
157	Fluoxetine* Capsule 20 mg
158	Haloperidol* Tablet 1.5 mg Haloperidol Tablet 5 mg Haloperidol Injection 5 mg/ml
159	Loperamide Tablet 2 mg
160	Metoclopramide Tablet 10 mg, Metoclopramide Oral Liquid 5 mg/5 ml Metoclopramide Injection 5 mg/m
161	Ondansetron Tablet 4 mg Ondansetron Oral Liquid 2 mg/5 ml Ondansetron Injection 2 mg/ml
162	Buprenorphine Tablet (sub-lingual) 0.4 mg5
163	Disulfiram Tablet 250/500 mg
164	Naltrexone Tablet 50 mg
165	Tramadol* Capsule 50 mg4 Tramadol Injection 50 mg/ml
166	Zoledronic Acid Powder for Injection 4 mg

167	Hyoscine Butyl- Bromide Tablet 500 mg Hyoscine Butyl- Bromide Injection 20 mg/ml
	Opioid Analgesic Medicines
168	Morphine* Injection 10 mg/ml6 Morphine Injection 15 mg/ml Morphine Tablet 10 mg Morphine Injection 10 mg/ml Morphine Tablet 10 mg Morphine Tablet 20 mg Morphine Tablet SR/30 mg
169	Codeine Tablet 15 mg Codeine Oral Solution 15 mg/5 ml6
170	Fentanyl Injection 50 mcg/ml6
171	Methadone Tablet 5 mg, 40 mg6 Methadone Oral solution 5 mg/ml Methadone Injection 10 mg/ml
	Anti-Parkinsonism Medicines
172	Levodopa (A) + Carbidopa (B) Tablet 100 mg (A) + 10 mg (B) CR Tablet 100 mg (A) + 25 mg (B) CR Tablet 200 mg (A) + 50 mg (B) Tablet 250 mg (A) + 25 mg (B)
173	Trihexyphenidyl (Benzhexol) Tablet 2 mg
	Medicines Affecting Blood
174	Clonidine Tablet 100 mcg
175	Erythropoietin Injection 2000 IU/ml Erythropoietin Injection 10000 IU/ml (Store in an air tight container at a temperature below - 200C. Avoid repeated freezing and thawing)
176	Ferrous Salts equivalent to 60 mg of Elemental Iron Ferrous Salts Oral Liquid equivalent to 25 mg of Elemental Iron/ml
177	Ferrous Salt (A) + Folic Acid (B): As per Anemia Mukt Bharat Abhiyan Children 06-59 months: Each ml of Iron and Folic Acid syrup containing 20 mg elemental Iron+ 100 mcg of Folic Acid. Children 05-9 years: Tablet 45 mg Elemental Iron (A) + 400 mcg (B)**[Pink Color]** Adolescent (10-19 Year): Tablet 60 mg Elemental Iron (A)+ 500 mcg (B) [Blue Color] Adult: Tablet 60 mg Elemental Iron (A)+ 500 mcg (B)[Red color]
178	Folic Acid* Tablet 5 mg Folic Acid Tablet 0.4 mg Folic Acid 5 mg Injection 1 mg/ml
179	Hydroxyurea Capsule 500 mg3
180	Iron Sucrose Injection 20 mg/ml (Protect from light and store at temperature not exceeding 300C)
181	Phytomenadione (Vitamin K1) Tablet 10 mg Phytomenadione (Vitamin K1) Inj 10 mg/ml (Protect from light)
182	Menadione Injection (Vitamin K3) 10 mg/ml (Protect from light)
183	Heparin Sodium Injection 1000 IU2
184	Tranexamic Acid Tablet 500 mg
185	Warfarin Tablet 1 mg2 Warfarin Tablet 2 mg Warfarin Tablet 3 mg Warfarin Tablet 5 mg
186	Coagulation factor VII
187	Coagulation factor VIII
188	Coagulation factor IX
189	APCC (Activated Prothrombin Complex Concentrate) Inhibitor
	Cardiovascular Medicines
190	Clopidogrel Tablet 75 mg

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

191	Diltiazem Tablet 60 mg Diltiazem SR Tablet 90 mg Diltiazem Injection 5 mg/ml
192	Glyceryl Trinitrate Sublingual Tablet 0.5 mg (Glyceryl trinitrate tablets are unstable) Glyceryl trinitrate Injection 125 mg/5 ml (Protect from light and moisture in glass container of not more than 100 tablets and store at temperature not exceeding 300C)
193	Isosorbide-5- mononitrate Tablet 10 mg Isosorbide-5- mononitrate SR Tablet 30 mg
194	Isosorbide Dinitrate Tablet 5 mg Isosorbide Dinitrate Tablet 10 mg
195	Atenolol Tablet 50 mg, 100 mg
196	Metoprolol Tablet 25 mg Metoprolol Tablet 50 mg Metoprolol Tablet 100 mg Metoprolol SR Tablet 25 mg Metoprolol SR Tablet 50 mg
197	Amiodarone Tablet 100 mg Amiodarone Injection 50 mg/ml
198	A mlodipine Tablet 2.5 mg A mlodipine Tablet 5 mg A mlodipine Tablet 10 mg (Protect from moisture)
199	Hydrochlorothiazid* Tablet 12.5 mg Hydrochlorothiazid Tablet 25 mg Hydrochlorothiazide Tablet 50 mg
200	Labetalol Injection 5 mg/ml Labetalol Tablet 100 mg Labetalol Injection 20 mg/2 ml
201	Methyldopa Tablet 250 mg Methyldopa Tablet 500 mg
202	Enalapril Tablet 2.5 mg Enalapril Tablet 5 mg Enalapril Tablet 10 mg
203	Captopril Tablet 25 mg
204	Lisinopril Tablet 5 mg
205	Verapamil Tablet 40 mg, 120 mg Verapamil Injection 5 mg/2 ml
206	Ramipril Tablet 2.5 mg/5 mg
207	Telmisartan Tablet 40 mg
208	Digoxin Tablet 0.25 mg Digoxin Tablet 250 mg
209	Dobutamine Injection 50 mg/ml
210	Dopamine Injection 40 mg/ml (Store in an airtight container protected from light)
211	Protamine Injection 50 mg/5 ml (Injection: Protect from light in a single dose container)
212	Noradrenaline Injection 2 mg/ml (Store in single dose containers. Store at room temperature (250C). Store in tight, light resistant containers as it is readily oxidized. Do not use if discolored (e.g. pink, dark yellow, brown) or if there is a precipitate)
213	Enoxaparin LMWH Injection
214	Clofibrate Tablet 500 mg

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

215	Streptokinase Injection 15 lac/Vial Sterptokinase Injection 7.5 lac/Vial (Store in a sealed container protected from light in refrigerator (2 to 80C). The container should be sterile and sealed so as to exclude micro-organisms)
216	Finofibrate Tablet 40 mg, 160 mg
217	Atorvastatin Tablet 10 mg Atorvastatin Tablet 40 mg (Protected from moisture and store at temperature not exceeding 300C)
218	Esmolol Injection 10 mg/ml
219	Sodium nitroprusside Injection 10 mg/ml (Protect from light)
220	Alteplase Powder for Injection 20 mg Alteplase Powder for Injection 50 mg (Protect from heat, light and moisture and store at room temperature (<30°C). Use reconstituted solution within 8 hours)
	Medicines used in Dementia
221	Donepezil Tablet 5 mg (Protect from moisture and at temperature not exceeding 250C)
	Dermatological medicines (Topical)
222	Clotrimazole cream 1% Clotrimazole Oral Lotion or Mouth Paint: 15 ml
223	Framycetin cream 0.5% (Protect from light and moisture and store at temperature not exceeding 300C. If the material is sterile, the container should be tamper-evident and sealed so as to exclude micro-organisms)
224	Fusidic Acid Cream 5 mg/10 gm preparation 2% or 20 mg per gram Fusidic Acid Cream 2%: 5 mg/10 mg preparation
225	Silver Sulphadiazine 2 to 4%
226	Miconazole Ointment or Cream 2% 15 gm preparation (Protected from light and moisture and store at temperature not exceeding 300C. If it is packed in aluminates; the inner surface of tubes should be coated with suitable lacquer)
227	Betamethasone Cream 0.05% Betamethasone Cream 0.1% Betamethasone Injection 12 mg Betamethasone Injection 4 mg/ml
228	Calamine Lotion
229	Benzoyl Peroxide Gel 2.5% Benzoyl Peroxide Gel 5%
230	Coal Tar Solution 5%
231	Salicylic Acid Ointment 6%
232	Gamma Benzene Hexa Chloride Lotion 100 ml (Protect from light)
233	Permethrin Lotion 1% Permethrin Cream 5%
234	Glycerin Oral Liquid
235	Petrolium Jelly 100%
	Diagnostic Agents
236	Lignocaine Eye Drops 4% (Store in cool place)
237	Tropicamide Eye Drops 1% (Store in a refrigerator (8 to 150C). It should not be allowed to freeze)
	Dialysis Solution
238	Haemodialysis Fluid

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

239	Intraperitoneal Dialysis Solution*
	Disinfectants and Antiseptics
240	Cetrimide Solution 20% (concentrate for dilution)
241	Chlorhexidine Solution 5% (concentrate for dilution)
242	Ethyl Alcohol (denatured) (Store in a tightly closed container at a temperature not exceeding 300C)(Away from fire and protected from moisture)
243	Hydrogen Peroxide Solution 6%
244	Povidone Iodine Solution 4% to 10% Povidone Iodine Solution 10% (equivalent to 1% available iodine)
245	Bleaching Powder containing not less than 30% w/w of available chlorine (as per I.P) (Protect from moisture in a tightly closed container)
	Diuretic Medicines
246	Furosemide Tablet 40 mg Furosemide Injection 10 mg/ml
247	Indapamide Tablet 1.5 mg
248	Chlorthalidone Tablet 12.5 mg3
249	Mephentermine Injection 15 mg/ml
250	Mannitol Injection 10% (Store at temperatures between 200 and 300C) Mannitol Injection 20% (Exposure to lower temperatures may cause the deposition of crystals)
251	Spironolactone Tablet 25 mg Spironolactone Tablet 50 mg Spironolactone Tablet 100 mg
252	Methyl Cellulose Tablet, Powder
	Dental Restorative Materials and Medicines
253	Zinc Oxide Eugenol
254	Silver Amalgam
255	Glass Ionomer Cement (GIC)
256	Calcium Hydroxide
257	Sodium Hypochloride
258	Gutta Percha (GP)
259	Light Cure Composite
260	Ketorolac 10 mg tablet
261	Gum Paint (Tannic Acid)
262	Povidine-iodine Germicide Gargle 20% w/v
263	Tooth Paste (Potassium Nitrate)
	Ear, Nose and Throat (ENT) Medicines
264	Ciprofloxacin Drops 0.3% Ciprofloxacin Eye/Ear Drops (Protect from light)
265	Clotrimazole Drops 1%
266	Xylometazoline* Nasal Drops 0.05 %, 0.1% Xylometazoline Nasal Drops: Paediatric (0.05), Adult (0.1%)
267	Ofloxacin Tablet 200 mg Ofloxacin Tablet 400 mg
268	Normal Saline Nasal Drops: Sodium Chloride Drops 0.05% w/v
269	Wax Solvent Ear Drops: Benzocaine, Paradichlorobenzene, Turpentine Oil
270	Boro-Spirit Ear Drops-0.183 gm Boric Acid in 2.08 ml of Alcohol

271	Combo Ear Drops-Chloramphenicol 5% w/v + Clotrimazole 1% +Lignocaine Hydrochloride 2%
272	Liquid Paraffin-Menthol Drops: Menthol 10 gm +Eucalyptus 2 ml+ Camphor 10 mg+ liquid paraffin to 100 ml
	Gastrointestinal Medicines
273	Omeprazole Capsule 20 mg
274	Ranitidine Tablet 150 mg Ranitidine Injection 25 mg/ml
275	Sucralfate Tablet 10 mg Sucralfate Oral Liquid 100 mg/ml
276	Metoclopramide Injection 5 mg/ml
277	Domperidone Tablet 10 mg Domperidone Oral Suspension 1 mg/ml; 30 ml bottle or 5 ml drops containing 10 mg/ml
278	Dicyclomine Tablet 10 mg (Tablets: Protect from light) Dicyclomine Injection 10 mg/ml, (Injection: Protect from light, in single dose or multiple dose containers) Dicyclomine Tablet 500 mg
279	Hyoscine Butyl- Bromide Tablet 500 mg Hyoscine Butyl- Bromide Injection 20 mg/ml
280	Drotaverine Tablet 500 mg
281	Bisacodyl Tablet 5 mg/10mg Bisacodyl Suppository 5 mg/10mg
282	Zinc Sulphate Tablet 10 mg Zinc Sulphate Dispersible Tablet USP eq. to Elemental Zinc 20 mg
283	Lactulose Oral Liquid* 10g/15 ml
284	Ispaghula- Granules, Husk, Powder (Protect from light and moisture)
285	Senna Tablet, Granules, Powder (Protect from light and moisture)
	Hormones, other Endocrine Medicines and Contraceptives
286	Human Chorionic Gonadotropin Injection 1000 IU Human Chorionic Gonadotropin Injection 5000 IU
287	Methylprednisolone Tablet 8 mg, 32 mg Methylprednisolone Injection 40 mg/ml Methylprednisolone Injection 500 mg
288	Ethinylestradiol (A) + Levonorgestrel (B) Tablet 0.03 mg (A) + 0.15 mg (B) Tablet 0.03 mg (A) + 0.15 mg (B) with Ferrous Fumarate
289	IUCD 380A IUCD 375
290	Male Condom
291	Tubal Ring
292	Ormeloxifene Tablet 30 mg
293	Ethinylestradiol Tablet 0.01 mg Ethinylestradiol Tablet 0.05 mg
294	Levonorgestrel Tablet 1.5 mg Levonorgestrel Tablet 0.75 mg
295	Glimepiride Tablet 1 mg Glimepiride Tablet 2 mg
296	Gliclazide Tablet 40 mg

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

297	Insulin (Soluble) Injection 40 IU/ml2,3 Insulin Lente Basal Injection Insulin Rapid Injection Insulin Mixtard
298	Metformin Tablet 500 mg3 Metformin Controlled released 750 mg
299	Premix Insulin 30:70 Injection (Regular: NPH)2 Premix Insulin 30:70 Injection 40 IU/ml3
300	Glibenclamide Tablet 2.5 mg3 Glibenclamide Tablet 5 mg
301	Medroxyprogesterone Tablet 5 mg, 10 mg Medroxyprogesterone acetate Injection 150 mg
302	Carbimazole Tablet 5 mg Carbimazole Tablet 10 mg
303	Levothyroxine Tablet 50,100mcg (Protect from light and moisture)
	Immunological/Vaccines
304	Anti-Rabies Immunoglobulin7
305	Anti-Tetanus Immunoglobulin7
306	Anti-D Immunoglobulin7
307	Diphtheria Antitoxin7
308	Hepatitis B Immunoglobulin7
309	Snake Venom Antiserum7 a) Soluble/Liquid Polyvalent b) Lyophilised Polyvalent
310	Rabies Vaccine7
311	As per Current Immunization Programme Guidelines (Stored as per manufacturer's instructions)
	Muscle Relaxants and Cholinesterase Inhibitors
312	Atracurium Injection 10 mg/ml (protect from light in single dose containers)
313	Succinylcholine Injection 50 mg/ml
314	Vecuronium Powder for Injection 4 mg Vecuronium Powder for Injection 10 mg
	Medicines for Neonatal Care
315	Caffeine Oral Liquid 20 mg/ml Caffeine Injection 20 mg/ml
	Ophthalmological Medicines
316	Acyclovir Ointment 3%
317	Ciprofloxacin Drops 0.3%
318	Gentamicin Drops 0.3% Gentamicin Injection 40 mg/ml
319	Povidone iodine Drops 0.6% Povidone iodine Drops 5%
320	Prednisolone Drops 0.1% Prednisolone Drops 1%
321	Acetazolamide Tablet 250 mg

322	Pilocarpine Drops 2% Pilocarpine Drops 4%
323	Timolol Drop 0.5%
324	Atropine Ointment 1%
325	Homatropine Drops 2%
326	Tropicamide Drops 1% (Store in a refrigerator (8 to 150C). It should not be allowed to freeze)
327	Carboxymethylcellulose Drops 0.5%
	Oxytocic and Anti-Oxytocic Medicines
328	Methylergometrine Injection 0.2 mg/ml
329	Mifepristone Tablet 200 mg
330	Misoprostol Tablet 100mcg Misoprostol Tablet 200mcg (oral/vaginal)
331	Combi-pack with Mifepristone + Misoprostol (1 tablet of Mifepristone 200 mg and 4 tablets of Misoprostol 200mcg)
332	Oxytocin Injection 5 IU/ml Oxytocin Injection 10 IU/ml
333	Nifedipine Tablet 10 mg Nifedipine Soft Gelatin Capsule 5 mg
	Psychotherapeutic Medicines
334	Chlorpromazine Tablet 100 mg
335	Clozapine Tablet 25 mg Clozapine Tablet 100 mg
336	Diphenylhydantoin Tablet 100 mg3
337	Fluphenazine Depot Injection 25 mg/ml
338	Risperidone* Tablet 2 mg Risperidone Injection
339	Phenobarbitone Tablet 30 mg1 Phenobarbitone Tablet 60 mg 5 Phenobarbitone Oral Liquid 20 mg/5 ml
340	Olanzapine* Tablet 5 mg Olanzapine Injection 10 mg
341	Escitalopram Tablet 10 mg Escitalopram Tab 5 mg
342	Imipramine Tablet 25 mg Imipramine Tablet 75 mg
343	Lithium Tablet 300 mg
344	Clonazepam Tablet 0.5 mg Clonazepam Tablet 0.25 mg
345	Zolpidem Tablet 10 mg4
	Medicines Acting on the Respiratory Rract
346	Budesonide Inhalation (MDI/DPI) 100 mcg/dose Budesonide Inhalation (MDI/DPI) 200 mcg/dose Budesonide Respirator solution for use in nebuliser 0.5 mg/ml Budesonide Respirator solution for use in nebuliser 1 mg/ml
347	Combination of LABA+ICS (Formoterol, Salmeterolol/Fluticasone) MDI, DPI (Protect from light, moisture and store at temperature not exceeding 300C)
348	Budesonide Nebulisation Solution
349	Ipravent/Levoline Nebulisation Solution

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

350	Budesonide (A)+ Formoterol (B) Inhalation (MDI/DPI) 100 mcg (A)+ 6 mcg (B) Inhalation (MDI/DPI) 200 mcg (A)+ 6 mcg (B) Inhalation (MDI/DPI) 400 mcg (A)+ 6 mcg (B)
351	Etofyllin B Plus (A), Anhydrous Theophylline IP (B) combination injection 84.7 mg/ml (A) + 25.3 mg/ml (B)
352	Ipratropium Inhalation (MDI/DPI) 20 mcg/dose Ipratropium Respirator solution for use in nebuliszer 250 mcg/ml
353	Levosalbutamol 50mcg/dose
354	Salbutamol Tablet 2 mg Salbutamol Tablet 4 mg Salbutamol Oral liquid 2 mg/5 ml Salbutamol Inhalation (MDI/DPI) 100 mcg/dose Salbutamol Respirator solution for use in nebuliser 5 mg/ml
355	Formoterol Inhaled Bronchodilator
356	Salmeterol Inhaled Bronchodilator
357	Tablet Theophylline (Store protected from moisture)
358	Tiotropium Inhalation (MDI) 9 mcg/dose Tiotropium Inhalation (DPI) 18 mcg/dose
359	Deriphyllin Tablet SR
360	Montelukast Tablet 5 mg Montelukast Tablet 10 mg Montelukast syrup
Solutions Correcting Water, Electrolyte Disturbances and Acid-Base Disturbances	
361	Dextrose IV Injection 5% w/v, 500 ml
362	Glucose Injection 5% Glucose Injection 10% Glucose Injection 25% Glucose Injection 50%
363	Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B)
364	Hydroxyethyl Starch 6%IP (6% Saline solution for infusion)
365	Oral Rehydration* Salts Oral Rehydration Powder 27.5 gm WHO Formula
366	Potassium Chloride Injection 150 mg/ml2 Potassium Chloride Oral Liquid 500 mg/5 ml
367	Ringer Lactate Injection (as per IP)
368	Sodium Bicarbonate Injection (as per IP)2
369	Sodium Chloride Injection 0.9%2
370	Sterile Water for Injection IP-05 ml
Vitamins and Minerals	
371	Ascorbic Acid (Vitamin C) Tablet 100 mg7 Ascorbic Acid (Vitamin C) Tablet 500 mg
372	Calcium Carbonate Tablet 250 mg Calcium Carbonate Tablet 500 mg
373	Calcium with Vitamin D Tablets USP Syrup Calcium with Phosphate in the ratio 2:1 with Vitamin D Tablet Calcium Carbonate 650 mg equivalent to Elemental Calcium 250 mg and Cholecalciferol USP 125 mg

Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

374	Cholecalciferol Tablet 1000 IU7 Cholecalciferol Tablet 60,000 IU Cholecalciferol Oral Liquid 400 IU/ml Cholecalciferol Granules 60,000 IU in Sachet Cholecalciferol Injection of 6,00,000 IU Vitamin D3 60,000 Granules in 1 gm Sachet
375	Nicotinamide Tablet 50 mg7
376	Multivitamin Tab/Cap
377	Pyridoxine Tablet 25 mg7 Pyridoxine Tablet 40 mg Pyridoxine Tablet 50 mg Pyridoxine Tablet 100 mg
378	Riboflavin Tablet 5 mg7
379	Thiamine Tablet 100 mg7 Thiamine Injection 100 mg/ml
380	Vitamin A Oral liquid 100000 IU/ml7
	Dressing
381	Dressing Bandage and Gauze with Band-Aid

ANNEXURE 3: ESSENTIAL DRUG LIST- CIVIL HOSPITAL, COMMUNITY HEALTH CENTER AND URBAN COMMUNITY HEALTH CENTER

S. No.	Medicine Name
	Anaesthetics Agent
1	Halothane gas for Inhalation (Protect from light and store at temperature not exceeding 25°C)
2	Isoflurane gas for Inhalation
3	Ketamine Injection 10 mg/ml1 Ketamine Injection 50 mg/ml
4	Nitrous oxide gas for Inhalation (Store under pressure in metal cylinders of the type conforming to the appropriate safety regulations and at temperature not exceeding 37⁰C)
5	Oxygen gas for Inhalation
6	Propofol Injection 10 mg/ml 2 (Should not allow to freeze)
7	Promethazine* Injection 25 mg/ml3 Promethazine Injection 50 mg/ml
8	Pentazocin Injection 30 mg/ml5 (Protect from light & moisture)
9	Thiopentane Injection 0.5 gm/1gm2
10	Bupivacaine Injection (0.5% IP), 5 mg/ml, 20 ml vial
11	Sevoflurane Inhalation (Only in DH)
12	Lignocaine Injection 2% Lignocaine Injection 4% Lignocaine Jelly Lignocaine Ointment 2-5% Lignocaine Injection 5%w/v
13	Lignocaine (A) + Adrenaline (B) Injection 1% (A) + 1:200000 (5 mcg/ml) (B) Injection 2% (A) + 1:200000 (5 mcg/ml) (B)
14	Atropine* Injection 0.6 mg/ml Atropine Injection 1mg/ml (Protect from light)
15	Midazolam* Injection 1 mg/ml 2,4 Midazolam Tablet 250 mg Midazolam Tablet 500 mg
	Non-opioid analgesics, antipyretics and nonsteroidal anti-inflammatory medicines
16	Acetylsalicylic acid* (Aspirin) Tablet 25 mg Acetylsalicylic acid (Aspirin) Tablet 75 mg Acetylsalicylic acid (Aspirin) Tablet 150 mg Acetylsalicylic acid (Aspirin) Tablet 300 mg
17	Diclofenac Tablet 50 mg Diclofenac Injection 25 mg/ml Diclofenac Injection 25 mg/3 ml Diclofenac Gel 1%W/W
18	Ibuprofen Tablet 200 mg Ibuprofen Tablet 400 mg Ibuprofen Syrup 100 mg/5 ml

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

19	Paracetamol* (Acetaminophen) Tablet 500 mg, Paracetamol (Acetaminophen) Injection 150 mg/ml Paracetamol (Acetaminophen) Syrup 125 mg/5 ml Paracetamol (Acetaminophen) Syrup 120 mg/5 ml, 60 ml bottle Paracetamol Syrup 125 mg/5 ml, 60 ml bottle
20	Mefenamic acid capsule 250 mg, 500 mg
21	Naproxen Tablet 500 mg
22	Tramadol Capsule 50 mg 4 Tramadol Capsule100 mg Tramadol Injection 50 mg/ml
23	Allopurinol Tablet 100 mg Allopurinol Tablet 300 mg
	Opioid Analgesic agents
24	Morphine Tablet 10 mg 6 Morphine Injection 10 mg/ml
25	Codeine Tablet 15 mg, 6 Codeine oral solution 15 mg/5 ml
26	Fentanyl Injection 50 mcg/ml 6 (Only in DH)
27	Methadone injection 10 mg/ml 6 (Only in DH)
28	Adrenaline (Epinephrine) Injection 1 mg/ml (Protect from light, preferably in containers filled with nitrogen)
29	Cetirizine Tablet 5 mg Cetirizine Tablet 10 mg Cetirizine Oral liquid 5 mg/5 ml
30	Hydrocortisone sodium succinate* Injection 100 mg Hydrocortisone sodium succinate Injection 200 mg
31	Hydroxyzine Syrup 10 mg/5ml Hydroxyzine Tablet 25 mg
32	Pheniramine maleate Injection 22.75 mg/ml
33	Chlorpheniramine Tablet 4 mg, 5 mg, 10 mg, 20 mg, 40 mg 3 Chlorpheniramine Oral liquid 2 mg/5 ml, 5 mg/5 ml
	Antidotes and other substances used in poisoning
34	Activated charcoal powder (as licensed)
35	Calcium gluconate* Injection 100 mg/ml Calcium gluconate Injection 1 gm, IV-10 ml amp
36	Desferrioxamine Injection 500 mg (Only in DH) (Protect from light in refrigerator (2-8^{0}C). Do not freeze)
37	Naloxone 0.4mgml Injection
38	Pralidoxime Chloride (2-PAM) 25 mg/ml Injection
39	Neostigmine Injection 0.5 mg/ml
	Anticonvulsants/Antiepileptics
40	Carbamazepine Tablet 100 mg, 200 mg Carbamazepine Oral liquid 100 mg/5 ml, 200 mg/5 ml
41	Levetiracetam Tablet 250 mg Levetiracetam Tablet 500 mg
42	Lorazepam Tablet 1 mg/2 mg5 Lorazepam Injection 1 mg/ml, 2 mg/ml

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

43	Magnesium sulphate Injection 500 mg/ml
44	Phenytoin Tablet 50 mg/100 mg, 300 mg, ER Tablet 300 mg Phenytoin Oral liquid 30 mg/5 ml, 125 mg/5 ml Phenytoin Injection 25 mg/ml, 50 mg/ml
45	Sodium valproate* Tablet 200 mg, 300 mg, 500 mg Sodium Valproate Oral Liquid 200 mg/5 ml
	Intestinal Anti- helminthics medicines
46	Albendazole Tablet 400 mg Albendazole Oral liquid 200 mg/5 ml
47	Diethylcarbamazine Tab 100 mg Diethylcarbamazine oral liquid 120 mg/5 ml (Protect from moisture)
48	Ivermectin Tablet 6 mg
	Anti-Fungal medicines
49	Clotrimazole Tablet 100 mg Clotrimazole Pessary Tablet 100 mg (Do not crush pessaries.)
50	Fluconazole Tablet 150 mg (Store in an airtight container)
51	Griseofulvin Tablet 125 mg, 250 mg
	Anti- Bacterial and other anti-infective medicines
52	Ampicillin Capsule 500 mg Ampicillin Injection 500 mg/ml
53	Amoxicillin Syrup 125 mg/5 ml Amoxicillin Tablet/capsule 250 mg Amoxicillin powder for suspension 125 mg/5 ml (Capsule, oral suspension: Store protected from moisture and light at a temperature not exceeding 30ºC)
54	Amoxicillin (A) + Clavulanic acid (B) Tablet 500 mg (A) + 125 mg (B) Tablet 875 mg (A) + 125 mg (B) Powder for Injection 500 mg (A) + 100 mg (B) Powder for Injection 1 g (A) + 200 mg (B)
55	Penicillin V Tablet 250mg
56	Benzathine benzylpenicillin Injection 12 lacs unit
57	Benzyl penicillin Powder for Injection 10 lac units
58	Cefazolin Injection 500 mg Cefazolin Injection 1 gm (The constituted solution should be stored protected from light and used within 24 hours when stored at a temperature not exceeding 30ºC or within 4 days when stored between 2 to 8º)
59	Cefixime Tablet 200 mg, 400 mg4 Cefixime Oral liquid 50 mg/5 ml
60	Cefotaxime Injection 250 mg4 Cefotaxime Injection 1 g
61	Ceftazidime Powder for Injection 250 mg 4 Ceftazidime Powder for Injection 1 g (Store in sterile containers sealed, so as to exclude micro-organisms protected from moisture at a temperature not exceeding 30ºC)
62	Cloxacillin Capsule 250 mg Cloxacillin oral liquid 125 mg/5 ml Cloxacillin Injection 500 mg/vial
63	Cefuroxime 250mg tablet Cefuroxime 1g Injection

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

64	Azithromycin Tablet 250 mg Azithromycin Tablet 500 mg Azithromycin Oral liquid 200 mg/5 ml
65	Norfloxacin Dispersible Tablet 100 mg Norfloxacin Tablet 400 mg
66	Ciprofloxacin* Tablet 250 mg, 500 mg Ciprofloxacin IV 200 mg/100 ml Ciprofloxacin Oral liquid 250 mg/5 ml
67	Clarithromycin Tablet 500 mg
68	Co-trimoxazole Tablet [Sulphamethoxazol (A) +Trimethoprim (B)] 400 mg (A) + 80 mg (B) 800 mg (A) + 160 mg (B) Oral liquid 200 mg (A) + 40 mg (B)/5 ml
69	Doxycycline Tablet 100 mg Doxycycline Syrup 50 mg/5 ml
70	Metronidazole Tablet 200 mg Metronidazole Tablet 400 mg (Protect from light and moisture. Store injection in a single dose container.)
71	Nitrofurantoin Tablet 100 mg Nitrofurantoin Oral liquid 25 mg/5ml
72	Amikacin Injection 100 mg2 Amikacin Injection 500 mg
73	Clofazimine Tablet 50 mg4 Clofazimine Capsule 100 mg, 200 mg
74	Delamanid 50 mg
75	Dapsone Tablet 25 mg Dapsone Tablet 100 mg
76	Capreomycin Injection 500 mg, 750 mg, 1 gm4
77	Cycloserine Capsule 125 mg/250 mg 4
78	Ethambutol Tablet 100 mg 4 Ethambutol Tablet 200 mg Ethambutol Tablet 400 mg Ethambutol Tablet 600 mg Ethambutol Tablet 800 mg
79	Tab Ethionamide 125 mg/250 mg4
80	Isoniazid Tablet 50 mg 4 Isoniazid Tablet 75 mg Isoniazid Tablet 100 mg Isoniazid Tablet 300 mg Isoniazid Oral liquid 100 mg/5 ml
81	Kanamycin Injection 500 mg 2 Kanamycin Injection 750 mg Kanamycin Injection 1 gm
82	Levofloxacin Tablet 250 mg 4 Levofloxacin Tablet 500 mg Levofloxacin Tablet 750 mg
83	Linezolid Tablet 600 mg
84	Ofloxacin Tablet 200 mg Ofloxacin Tablet 400 mg
85	Moxifloxacin Tablet 400 mg Moxifloxacin Tablet 500 mg
86	Sodium Amino salicylate granules 10 gm/9.2 gms4 Para- amino salicylic acid Tablet 500 mg
87	Pyrazinamide Tablet 150 mg, 400 mg, 500 mg, 750 mg4 Pyrazinamide Oral liquid 250 mg/5
88	Rifabutin Capsule 150 mg4

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

89	Rifampicin Tablet 75 mg 4 Rifampicin Capsule 150 mg, 300 mg, 450 mg, 600 mg Rifampicin Oral liquid 100 mg/5 ml
90	Injection Streptomycin 750 mg/1000 mg 2 Injection Streptomycin 500 mg
91	Bedaquiline Tablet 100 mg
92	Diloxanide furoate Tablet 500 mg
	Anti-Viral medicines
93	Acyclovir Tablet 200 mg (Store tablets protected from light.)
	Anti-Malarial medicines
94	Tab Artemether (A) (As pe NVBDC program guideline by GoI) + Lumefantrine (B) Tablet 20 mg (A) + 120 mg (B) Tablet 40 mg (A) + 240 mg (B) Tablet 80 mg (A) + 480 mg (B) Oral liquid 80 mg (A) + 480 mg (B)/5 ml
95	Artesunate (A) + Sulphadoxine - Pyrimethamine (B) combi pack (A+B) ACT- SP less than 1 year-Pink Color: 3 Tablet 25 mg (A) + 1 Tablet (250 mg + 12.5 mg)(B) ACT -SP (2-4 years) Yellow Color: 3 Tablet 50 mg (A) + 1 Tablet (500 mg + 25 mg) (B) ACT- SP (5-8 years) Green Color: 3 Tablet 100 mg (A) + 1 Tablet (750 mg + 37.5 mg) ACT- SP (9-14 years) Red Color: 3 Tablet 150 mg (A) + 2 Tablet (500 mg + 25 mg) ACT- SP (Adult/Above 15 Years) White Color 3 Tablet 200 mg (A) + 2 Tablet (750 mg + 37.5 mg) (B) OR 3 Tablet (500 mg + 25 mg) (B) [As per NVBDC program guideline by GoI]
96	Chloroquine Tablet 150 mg [As per NVBDC program guideline by GoI] Chloroquine Oral liquid 50 mg/5 ml
97	Hydroxychloroquine tablet 200 mg, 400 mg
98	Artesunate Powder for injection 120 mg [As per NVBDC program guideline by GoI]
99	Primaquine Tablet 2.5 mg Primaquine Tablet 7.5 mg Primaquine Tablet 15 mg (Protect from moisture) [As per NVBDC program guideline by GoI]
100	Quinine Tablet 300 mg [As per NVBDC program guideline by GoI] (Protect from light)
	Anti-COVID-19 Medicines
101	Favipiravir Tablet 200 mg, 400 mg
102	Remdesivir Injection 100 mg/20 ml
	Medicines used in palliative care
103	Diazepam* Tablet 5 mg 5 Diazepam Injection 5 mg/ml, 10 mg/2 ml Diazepam Oral liquid 2 mg/5 ml Diazepam Suppository 5 mg (Injection: store in single dose or multi dose container protected from light)
	Anti-parkinsonism medicines
104	Levodopa (A) + Carbidopa (B) Tablet 100 mg (A) + 10 mg (B) Tablet 100 mg (A) + 25 mg (B) CR Tablet 100 mg (A) + 25 mg (B) CR Tablet 200 mg (A) + 50 (B) mg Tablet 250 mg (A) + 25 mg (B)
105	Trihexyphenidyl Tablet 2 mg
	Medicines affecting blood
106	Ferrous salts equivalent to 60 mg of elemental iron Oral liquid equivalent to 25 mg of elemental iron/ml

Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

107	Ferrous Salt (A) + Folic Acid (B): As per Anemia Mukt Bharat Abhiyan Children 06-59 months: Each ml of Iron and Folic Acid syrup containing 20 mg elemental Iron+ 100 mcg of Folic Acid. Children 05-9 years: Tablet 45 mg Elemental Iron (A) + 400 mcg (B)**[Pink Color]** Adolescent (10-19 Year): Tablet 60 mg Elemental Iron (A)+ 500 mcg (B) [Blue Color] Adult: Tablet 60 mg Elemental Iron (A)+ 500 mcg (B)[Red color]
108	Folic acid Tablet 5 mg
109	IFA syrup
110	Hydroxyurea Capsule 500mg
111	Iron sucrose Injection 20 mg/ml (Protect from light and store at temperature not exceeding 30ºC.)
112	Phytomenadione (Vitamin K1) Tablet 10 mg Phytomenadione (Vitamin K1) Injection 10 mg/ml (Protect from light.)
113	Menadione Injection (Vitamin K3) 10 mg/ml (Protect from light.)
114	Tranexamic acid Tablet 500 mg
115	Streptokinase Injection 15 lac/vial Streptokinase Injection 7.5 lac/Vial (Store in a sealed container protected from light in refrigerator (2 to 8ºC). The container should be sterile and sealed so as to exclude micro-organisms.)
116	Heparin Sodium Injection 1000 IU2
117	Warfarin Tablet 1 mg 2 Warfarin Tablet 2 mg Warfarin Tablet 5 mg
	Cardiovascular medicines
118	Clopidogrel Tablet 75 mg
119	Diltiazem Tablet 60 mg Diltiazem SR Tablet 90 mg
120	Glyceryl trinitrate Sublingual Tablet 0.5 mg Glyceryl trinitrate 125 mg/5ml (Glyceryl trinitrate tablets are unstable) (Store protected from light and moisture in glass container of not more than 100 tablets at a temperature not exceeding 30ºC.)
121	Isosorbide dinitrate Tablet 5 mg Isosorbide dinitrate Tablet 10 mg
122	Isosorbide-5- mononitrate Tablet 10 mg Isosorbide-5- mononitrate SR Tablet 30 mg
123	Atenolol Tablet 50 mg/100 mg
124	Metoprolol Tablet 25 mg Metoprolol Tablet 50 mg Metoprolol Tablet 100 mg Metoprolol SR Tablet 25 mg
125	Propranolol Tablet 40 mg
126	Amiodarone Tablet 100 mg
127	Amlodipine Tablet 2.5 mg/5 mg (Protect from moisture.) Amlodipine Ta blet 10 mg
128	Indapamide Tablet 1.5 mg
129	Chlorthalidone Tablet 12.5 mg
130	Injection Mannitol
131	Labetalol Injection 20 mg
132	Methyldopa Tablet 250

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

133	Enalapril Tablet 2.5 mg Enalapril Tablet 5 mg Enalapril Tablet 10 mg
134	Captopril Tablet 25 mg
135	Lisinopril Tablet 5 mg
136	Telmisartan Tablet 40 mg
137	Digoxin Tablet 250 mg
138	Dopamine Injection 40 mg/ml (Store in an airtight container protected from light.)
139	Noradrenaline Injection 2 mg/ml (Store in single dose containers. Store at room temperature (25ºC). Store in tight, light resistant containers as it is readily oxidized. Do not use if discolored (e.g., pink, dark yellow, brown) or if there is a precipitate.)
140	Enoxaparin Injection LMWH
141	Atorvastatin Tablet 10 mg (Protect from moisture and store at temperature not exceeding 30ºC.) Atorvastatin Tablet 40 mg
	Medicines used in Dementia
142	Donepezil Tablet 5 mg (Protect from moisture and store at a temperature not exceeding 25ºC.)
	Dermatological medicines (Topical)
143	Clotrimazole Cream 1% Clotrimazole Oral Lotion or mouth paint: 15 ml
144	Framycetin Cream 0.5% (Protect from light, moisture and store at temperature not exceeding 30ºC. If the material is sterile, the container should be tamper-evident and sealed so as to exclude micro-organisms.)
145	Fusidic Acid Cream 5 mg/10 gm preparation 2% or 20 mg per gram Fusidic Acid Cream 2%: 5 mg/10 mg Preparation
146	Silver sulphadiazine Cream 2 to 4 %
147	Miconazole Ointment or Cream 2% 15 gm preparation (Protect from light, moisture and store at temperature not exceeding 30ºC. If it is packed in aluminates; the inner surface of tubes should be coated with suitable lacquer.)
148	Betamethasone Cream 0.05%/0.1%
149	Calamine lotion
150	Benzoyl peroxide 2.5%/5%
151	Coal tar solution 5%
152	Salicylic acid Ointment 6%
153	Gamma Benzene Hexa Chloride Lotion 100 ml (Protect from light.)
154	Permethrin Lotion 1% Permethrin Cream 5%
155	Glycerin Oral liquid
156	Petroleum Jelly 100%
	Diagnostic agents
157	Lignocaine Eye drop 4% (Store in cool place.)
158	Tropicamide Eye drop 1% (Store in a refrigerator (8 to 15ºC). It should not be allowed to freeze)

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

159	Cetrimide Solution 20% (Concentrate for dilution)
160	Chlorhexidine Solution 5% (Concentrate for dilution)
161	Ethyl alcohol (Denatured) (Store in a tightly closed container at a temperature not exceeding 30ºC. Away from fire and protected from moisture.)
162	Hydrogen peroxide Solution 6%
163	Sodium Hypochlorite
164	Povidone iodine Solution 4% to 10% Povidone iodine Solution 10% (equivalent to 1% available iodine)
165	Bleaching powder Containing not less than 30% w/w of available chlorine (as per I.P) (Protect from moisture in a tightly closed container.)
166	Potassium permanganate Crystals for topical solution
	Diuretics Medicines
167	Furosemide Tablet 40 mg Furosemide Injection 10 mg/ml
168	Hydrochlorothiazide* Tablet 12.5 mg Hydrochlorothiazide Tablet 25mg
169	Spironolactone Tablet 25 mg
170	Methyl Cellulose tablet/powder
171	Ciprofloxacin Drops 0.3 % Ciprofloxacin Eye/Ear drops (Protect from light)
172	Normal Saline nasal drop: sodium chloride drops 0.05% w/v
173	Xylometazoline nasal drop: Pediatric (0.05) and adult (0.1%)
174	Wax solvent ear drops: benzocaine, paradicholorobenzene, turpentine oil
175	Boro-spirit ear drop-0.183 gm boric acid in 2.08 ml of alcohol
176	Combo ear drop-Chloramphenicol 5% w/v + clotrimazole 1% +Lignocaine hydrochloride 2%
177	Liquid paraffin-menthol drop: Menthol 10 gm +Eucalyptus 2 ml+ Camphor 10 mg+ liquid paraffin to 100 ml
	Gastrointestinal medicines
178	Omeprazole Capsule 20 mg
179	Ranitidine Tablet 150 mg Ranitidine Injection 25 mg/ml
180	Pantoprazole 40mg Injection
181	Sucralfate Tablet 10 mg Sucralfate Oral liquid 100mg/ml
182	Ondansetron Oral Liquid 2 mg base/5 ml; syrup 30 ml bottle Ondansetron tablet 4 mg Ondansetron Injection 2 mg/ml
183	Metoclopramide Injection 5 mg/ml
184	Domperidone Tablet 10 mg Domperidone Oral Suspension 1 mg/ml; 30 ml bottle or 5 ml drops containing 10 mg/ml
185	Dicyclomine Tablet 10 mg (Injection: Protect from light, in single dose or multiple dose containers.) Dicyclomine Injection 10 mg/ml Dicyclomine Tablet 500 mg (Tablets: Protect from light)
186	Hyoscine butyl bromide Injection 20 mg/ml
187	Bisacodyl Tablet 5 mg/10 mg Bisacodyl suppository 5 mg/10mg

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

188	Zinc sulphate Tablet 20 mg Zinc sulphate Dispersible Tablet USP eq. to Elemental Zinc 20 mg
189	Lactulose Oral liquid 10 g/15 ml
190	Ispaghula- Granules/Husk/Powder (Protect from light and moisture)
191	Senna tablet/granules/Powder (Protect from light and moisture)
	Hormones, other endocrine medicines and contraceptives
192	Dexamethasone Injection 4 mg/ml. Dexamethasone Tablet 0.5 mg
193	Methylprednisolone Tablet 4 mg Methylprednisolone Tablet 8 mg
194	Prednisolone Tablet 5 mg, 10 mg
195	Ethinylestradiol Tablet 0.01 mg Ethinylestradiol Tablet 0.05 mg
196	Levonorgestrel Tablet 0.75 mg Levonorgestrel Tablet 1.5 mg
197	Gliclazide Tablet 40mg
198	Medroxyprogesterone acetate Tablet 5 mg Medroxyprogesterone acetate Injection 150 mg
199	Family Planning medicines and commodities
	Thyroid and Antithyroid medicines
200	Carbimazole Tablet 5 mg
201	Levothyroxine Tablet 50 mcg, 100 mcg (Protect from light and moisture.)
	Antidiabetic medicines
202	Glimepiride Tablet 1 mg/2 mg
203	Insulin (Soluble) Injection 40 IU/ml 2,3
204	Metformin Tablet 500 mg 3 Metformin Controlled released 750 mg
205	Premix Insulin 30:70 Injection (Regular: NPH) 2,3 Premix Insulin 30:70 Injection 40 IU/ml.
206	Glibenclamide Tablet 2.5 mg/5 mg3
207	Norethisterone 5 mg Tablet
	Immunological/Vaccines
208	Diphtheria antitoxin
209	Hepatitis B immunoglobulin7
210	Snake venom antiserum*7 Soluble/liquid polyvalent Lyophilized polyvalent
211	BCG vaccine7 [As per UIP Guideline by Govt. of India]
212	DPT + Hib + Hep B vaccine7 [As per UIP Guideline by Govt. of India]
213	DPT vaccine 7 [As per UIP Guideline by Govt. of India]
214	Hepatitis B vaccine 7 [As per UIP Guideline by Govt. of India]
215	Japanese encephalitis vaccine 7 [As per UIP Guideline by Govt. of India] (In the selected districts only)
216	Measles vaccine [As per UIP Guideline by Govt. of India]

Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

217	Oral poliomyelitis vaccine 7 [As per UIP Guideline by Govt. of India]
218	Tetanus toxoid 7 [As per UIP Guideline by Govt. of India]
219	Inactivated Polio Vaccine (IPV) 7 [As per UIP Guideline by Govt. of India]
220	Pneumococcal Conjugated Vaccine (PCV) 7 [As per UIP Guideline by Govt. of India]
221	Measles Rubella vaccine (MR) 7 [As per UIP Guideline by Govt. of India]
222	Rabies vaccine 7 Anti- Rabies Immunoglobulin
223	As per current immunization programme guidelines (Stored as per manufacturer's instructions.)
224	Vecuronium Powder for Injection 4 mg
	Ophthalmological Medicines
225	Acyclovir Ointment 3%
226	Atropine 1% Drops
227	Gentamicin Drops 0.3% Gentamicin Injection 40 mg/ml
228	Povidone iodine Drops 0.6% Povidone iodine Drops 5%
229	Prednisolone Drops 0.1% Prednisolone Drops 1%
230	Acetazolamide Tablet 250 mg
231	Pilocarpine Drops 2% Pilocarpine Drops 4%
232	Timolol Drop 0.5%
233	Atropine Ointment 1%
234	Homatropine Drops 2%
235	Tropicamide Drops 1% (Store in a refrigerator (8 to 15ºC). It should not be allowed to freeze)
236	Carboxymethylcellulose Drops 0.5%
237	Erythromycin 0.5% ointment
	Oxytocic and Anxiolytics
238	Mifepristone Tablet 200 mg
239	Misoprostol Tablet 100 mcg Misoprostol Tablet 200 mcg (oral/vaginal)
240	Oxytocin Injection 5 IU/ml Oxytocin Injection 10 IU/ml
241	Methylergometrine 0.125 mg Tablet Methylergometrine 0.2 mg/ml Injection
242	Nifedipine Tablet 10 mg Nifedipine Soft gelatin Capsule 5 mg
	Psychotherapeutic medicines
243	Chlorpromazine Tablet 100 mg
244	Diphenylhydantoin Tablet 100 mg 3
245	Fluphenazine Depot Injection 25 mg/ml
246	Haloperidol Tablet 5 mg Haloperidol Injection

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

247	Phenobarbitone Tablet 30 mg1 Phenobarbitone oral liquid 20 mg/5 ml 5
248	Risperidone Tablet 2 mg.
249	Olanzapine Tablet 5 mg
250	Amitriptyline Tablet 25 mg Amitriptyline Tablet 75 mg
251	Escitalopram Tablet 5 mg Escitalopram Tablet 10 mg
252	Fluoxetine Capsule 20 mg
253	Imipramine Tablet 75 mg Imipramine Tablet 25 mg
254	Lithium Tablet 300 mg
255	Clonazepam Tablet 0.25 mg
	Medicines acting on the respiratory tract
256	Budesonide Inhalation (MDI/DPI) 100 mcg/dose Budesonide Respirator solution for use in nebulizer 0.5 mg/ml
257	Budesonide (A)+ Formoterol (B) Inhalation (MDI/DPI) 100 mcg (A)+ 6 mcg (B) Inhalation (MDI/DPI) 200 mcg (A)+ 6 mcg (B) Inhalation (MDI/DPI) 400 mcg (A)+ 6 mcg (B)
258	Combination of LABA+ICS (Formoterol, Salmeterol/Fluticasone) MDI, DPI (Protect from light, moisture and store at temperature not exceeding 30ºC) (Protect from light, moisture and store at temperature not exceeding 30ºC.)
259	Etofylline B Plus (A), Anhydrous Theophylline IP (B) combination injection 84.7 mg/ml (A) + 25.3 mg/ml (B)
260	Ipratropium Inhalation (MDI/DPI) 20 mcg/dose Ipratropium Respirator solution for use in nebulizer 250 mcg/ml.
261	Levosalbutamol 50 mcg/dose
262	Salbutamol Tablet 2 mg/4 mg Salbutamol 100 mg/dose Salbutamol Oral liquid 2 mg/5 ml
263	Theophylline Tablet (Protect from moisture.)
264	Syrup Salbutamol Salbutamol Nebulizing solution.
265	Tiotropium Inhalation (MDI) 9 mcg/dose Tiotropium Inhalation (DPI) 18 mcg/dose
266	Deriphyllin SR Tablet
267	Montelukast Tablet 5 mg Montelukast syrup
268	N Acetyl Cystine Tablet 600 mg/Dispersible
269	Betamethasone Injection 4 mg/ml
	Solutions correcting water, electrolyte disturbances and acid-base disturbances
270	Dextrose IV Injection 5%w/v, 500ml
271	Glucose Injection 5% Glucose Injection 10% Glucose Injection 25% Glucose Injection 50%
272	Glucose (5%) + Sodium chloride (0.9%) Injection

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

273	Hydroxyethyl Starch 6% IP (6% Saline solution for infusion)
274	Oral rehydration salts* (ORS) Oral Rehydration powder 27.5 gm WHO Formula
275	Potassium chloride Injection 150 mg/ml 2 Potassium chloride Oral liquid 500 mg/5 ml
276	Ringer lactate solution (as per IP)
277	Sodium bicarbonate Injection (as per IP) 2
278	Sodium Chloride 0.9%
279	Water for Injection
	Vitamins and minerals
280	Ascorbic acid (Vitamin C) Tablet 100 mg 7 Ascorbic acid (Vitamin C) Tablet 500 mg
281	Calcium carbonate Tablet 250 mg Calcium carbonate Tablet 500 mg
282	Calcium with Vitamin D tablets USP Syrup Calcium with Phosphate in the ratio 2:1 with Vitamin D Tablet Calcium Carbonate 650 mg equivalent to elemental calcium 250 mg and Cholecalciferol USP 125 mg
283	Cholecalciferol Granules 60,000 IU in Sachet 7 Cholecalciferol Injection of 6,00,000 IU Vitamin D3 60,000 granules in 1gm sachet
284	Nicotinamide Tablet 50 mg7
285	Multivitamin Tab/Cap
286	Pyridoxine Tablet 40 mg7 Pyridoxine Tablet 50 mg Pyridoxine Tablet 100 mg
287	Riboflavin Tablet 5 mg7
288	Thiamine Tablet 100 mg7 Thiamine Injection 100 mg/ml
289	Vitamin A Oral liquid 100000 IU/ml 7
	Dental restorative materials and medicines
290	Zinc Oxide Eugenol
291	Silver Amalgam
292	Glass ionomer cement (GIC)
293	Calcium Hydroxide
294	Sodium Hypochlorite*
295	Gutta Percha (GP)
296	Light Cure composite
297	Ketorolac 10 mg tablet
298	Gum Paint (Tannic Acid)
299	Povidone-iodine Germicide Gargle 20% w/v
300	Toothpaste (Potassium Nitrate)

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

ANNEXURE 4: ESSENTIAL DRUGS LIST PRIMARY HEALTH CENTER, PRIMARY HEALTH CENTER- AAM, AND URBAN PRIMARY HEALTH CENTER

S. No.	Medicine
	Anesthetics Agent
1	Oxygen gas for inhalation
2	Lignocaine Injection 2% Lignocaine Topical form 2%
3	Lignocaine Injection 2% + Adrenaline Injection 1:200000 (5 mcg/ml)
4	Atropine Injection 0.6 mg/ml Atropine Injection 1 mg/ml
5	Midazolam Injection 1 mg/ml
6	Ketamine Injection10 mg/ml (Should be stored in lock and key) (Schedule X -prescription shall be in duplicate and one copy of which shall be retained by the licensee for a period of 2 Years)
7	Injection Thiopentone 500 mg
8	Bupivacaine Injection (Sensorcain) 0.5 mg
9	Neostigmine Injection 0.5 mg/ml
10	Vecuronium Powder for Injection 4 mg
11	Pentazocine Injection 30 mg/ml*
	Analgesics, antipyretics, non-steroidal anti-inflammatory medicines, medicines used to treat gout and disease modifying agents used in rheumatoid disorders
12	Asprin (Acetylsalicylic acid) Tablet 150 mg Asprin (Acetylsalicylic acid) Tablet 75 mg (Not to be used in suspected dengue patients and other clinical conditions without prescription)
13	Diclofenac Tablet 50 mg Diclofenac Injection 25 mg/ml Diclofenac Gel 1%W/W
14	Ibuprofen Tablet 200 mg (Not to be used in suspected dengue patients and other clinical conditions without prescription)
15	Ibuprofen Oral Liquid 100 mg/5 ml, 50 ml bottle (Not to be used in suspected dengue patients and other clinical conditions without prescription) (Recommended by RBSK Program Division)
16	Paracetamol Tablet 500 mg, Paracetamol Tablet 100 mg Paracetamol Syrup 125 mg/5 ml Paracetamol Suppository 100 mg
	Anti-allergics and medicines used in anaphylaxis
17	Levocetirizine Tablet 5mg Levocetrizine Oral liquid 2.5 mg/5 ml (Paediatric Use)
18	Chlorpheniramine Tablet 4 mg
19	Dexamethasone Tablet 0.5 mg Dexamethasone Injection 4 mg/ml
20	Hydrocortisone Succinate Injection 100 mg
21	Pheniramine Injection 22.75 mg/ml
22	Prednisolone Tablet 5 mg Prednisolone Oral liquid 5 mg/5 ml
23	Hydroxyzine oral syrup
24	Betamethasone Injection 4 mg per 1 ml in 1 ml ampule
	Anti-dotes and other substances used in poisoning
25	Activated charcoal

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

26	Calcium gluconate Injection 100 mg/ml
27	Snake venom antiserum Injection
	Anti-convulsants/Anti-epileptics
28	Magnesium Sulfate Injection (50% solution), 2 ml ampoule
29	Diazepam Oral liquid 2 mg/5 ml Diazepam Injection 5 mg/ml Diazepam Tablet 5 mg*
30	Phenobarbitone Tablet 30 mg Phenobarbitone Oral liquid 20 mg/5 ml
31	Phenytoin Tablet 50 mg Phenytoin Tablet 300 mg Phenytoin ER Tablet 300 mg Phenytoin Injection 25 mg/ml
32	Sodium valproate Tablet 250 mg Sodium valproate Tablet 500 mg Sodium valproate Syrup each 5 ml contains 200 mg
33	Midazolam Nasal Spray* (For emergency purpose)
34	Carbamazepine Tablet 100 mg Carbamazepine Tablet 200 mg
35	Diphenylhydantoin Tablet 100 mg
	Intestinal Anthelmintics
36	Albendazole Tablet 400 mg Albendazole Oral liquid 200 mg/5 m
	Anti-filarial
37	Diethylcarbamazine Tablet 100 mg Diethylcarbama
	Anti-bacterial
38	Amoxicillin Capsule 250 mg Amoxicillin Capsule 500 mg Amoxicillin Oral liquid 250 mg/5 ml
39	Amoxicillin 500 mg + Clavulanic acid 125 mg Tablet
40	Azithromycin Tablet 250 mg Azithromycin Tablet 500 mg Azithromycin Oral liquid 200 mg/5 ml
41	Ciprofloxacin Tablet 250 mg Ciprofloxacin Tablet 500 mg Ciprofloxacin Oral liquid 250 mg/5ml
42	Cefixime Tablet 200 mg Cefixime Oral liquid 50 mg/5 ml Cefixime Oral liquid 100 mg/5 ml*
43	Tab Co-trimoxazole [Sulphamethoxazol 80 mg +Trimethoprim 400 mg] Tab. 20 mg trimethoprim + 100 mg sulphamethoxazole Co-trimoxazole Oral Liquid [Sulphamethoxazol e 200 mg + Trimethoprim 40 mg/5 ml]
44	Gentamicin Injection 10 mg/ml Gentamicin Injection 80 mg/ml
45	Doxycycline Capsule 100 mg Doxycycline Dry Syrup 50 mg/5 ml
46	Norfloxacin tab/oral liquid
47	Penicillin V Tablet 250 mg
48	Benzyl penicillin Powder for Injection 10 lac units
49	Cefazolin Injection 500 mg Cefazolin Injection 1 gm
50	Cefotaxime Injection 250 Cefotaxime Injection 500 mg Cefotaxime Injection 1 g*
51	Ceftriaxone Injection 250 Ceftriaxone Injection 500 mg Ceftriaxone Injection 1 g*
	Anti-leprosy medicines
52	As per current program guidelines (Adults and Pediatrics)
	Anti-tuberculosis medicines
53	As per current program guidelines (Adults and Pediatrics)
	Anti-fungal medicines
54	Clotrimazole Pessary 100 mg Clotrimazole Vaginal Tablet Clotrimazole Drops 1% Clotrimazole Cream 1%
55	Fluconazole Tablet 150 mg

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

56	Miconazole ointment Miconazole Tablet
	Anti-protozoal medicines
57	Metronidazole Tablet 200 mg Metronidazole Tablet 400 mg Metronidazole Oral liquid 200 mg/5 ml
	Anti-malarial medicines
58	As per program guidelines (Adults and Pediatrics)- As per NVBDCP Guideline
	Medicines used in Palliative care
59	Amitriptyline Tablet 10 mg Amitriptyline Tablet 25 mg
60	Lactulose Oral liquid 10 g/15 ml
61	Tramadol capsule 50 mg* (Should be stored in double lock and key)
62	Povidone Iodine Lotion and Ointment
63	Ethamsylate Tablet
64	Deriphylline Tablet sustained release
	Anti-parkinsonism medicines
65	Levodopa (A) + Carbidopa (B) 100 mg (A) + 10 mg (B)
	Anti-anemia medicines
66	Ferrous Salt (A) + Folic Acid (B): As per Anemia Mukt Bharat Abhiyan Children 06-59 months: Each ml of Iron and Folic Acid syrup containing 20 mg elemental Iron+ 100 mcg of Folic Acid. Children 05-9 years: Tablet 45 mg Elemental Iron (A) + 400 mcg (B)**[Pink Color]** Adolescent (10-19 Year): Tablet 60 mg Elemental Iron (A)+ 500 mcg (B) [Blue Color] Adult: Tablet 60 mg Elemental Iron (A)+ 500 mcg (B)[Red color]
67	Folic acid Tablet 5 mg Folic acid Tablet 400 mcg
68	IFA Syrup
69	Phytomenadione Injection 10 mg/ml
70	Clopidogrel Tablet 75 mg
71	Diltiazem Tablet 60 mg Diltiazem Tablet 90 mg SR
72	Isosorbide-5- mononitrate Tablet 5 mg
73	Metoprolol Tablet 25 mg Metoprolol SR Tablet 25 mg Metoprolol SR Tablet 50 mg
74	Isosorbide dinitrate Tablet 5 mg (sublingual)
75	Dopamine Injection 40 mg/ml
76	Hydroxyurea Capsule 100mg, 300mg, 500mg
	Anti-hypertensive medicine
77	Amlodipine Tablet 2.5 mg Amlodipine Tablet 5 mg
78	Enalapril Tablet 5 mg
79	Hydrochlorothiazide Tablet 12.5 mg Hydrochlorothiazide Tablet 25 mg
80	Labetalol Tablet 100 mg Labetalol Injection 5 mg/ml
81	Methyldopa Tablet 250 mg
82	Telmisartan Tablet 40 mg
	Medicines used in shock and heart failure
83	Adrenaline Injection 1 mg/ml
	Hypolipidemic medicines
84	Atorvastatin Tablet 10 mg

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

	Dermatological medicines (Topical)
85	Framycetin Cream 0.5%
86	Silver sulphadiazine Cream 1%
87	Calamine Lotion
88	Betamethasone Cream 0.1%
89	Benzoyl peroxide Gel 2.5%
90	Benzyl Benzoate ointment/lotion
91	Mupirocin Ointment
92	Potassium Permanganate 0.1%
93	Zinc Oxide cream 10%
94	Fusidic Acid Cream 5mg/10gm preparation 2% or 20mg per gram Fusidic Acid Cream 2%: 5 mg/10 mg Preparation
95	Pemethrin Cream 5%
	Disinfectants and antiseptics
96	Cetrimide Solution 20% (concentrate for dilution)
97	Chlorhexidine Solution 5 (Concentrate for dilution)
98	Ethyl alcohol (Denatured) Solution 70%
99	Hydrogen peroxide Solution 6%
100	Methylrosanilinium chloride (Gentian Violet)
101	Bleaching powder Containing not less than 30% w/w of available chlorine (as per I.P)
102	Gama Benzene Hexachloride
	Diuretics
103	Furosemide Tablet 40 mg Furosemide Injection 10 mg/ml
104	Mannitol Injection 10% Mannitol Injection 20%
	Ear, nose and throat medicines
105	Xylometazoline Nasal drops 0.05 % Xylometazoline Nasal drops 0.1 %
106	Wax solvant ear drops: benzocaine, chlorbutol, paradicholorobenzene, turpentaine oil
107	Combo ear drop-Chloramphenicol 5% w/v +clotrimazole 1% +Lignocaine hydrochloride 2%
108	Normal saline nasal drops (.05%w/v)
109	Boro-Spirit ear drop
110	Ofloxacin Tablet 200 mg Ofloxacin Tablet 400 mg
	Gastrointestinal medicines
111	Omeprazole Capsule 20 mg
112	Ranitidine Injection
113	Metoclopramide Tablet 10 mg Metoclopramide Oral liquid 5 mg/5 ml Metoclopramide Injection 5 mg/ml
114	Ondansetron Tablet 4 mg Ondansetron Oral liquid 2 mg/5 ml Ondansetron Injection 2 mg/ml
115	Domperidone Tablet 10 mg Domperidone Syrup
116	Hyoscinebutylbromide Tablet 10 mg Hyoscinebutylbromide Injection 20 mg/ml
117	Ispaghula Granules/Husk/Powder (Herbal medicine)
118	Drotavarin Tablet 500 mg

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

119	Bisacodyl Tablet 5 mg/10mg Bisacodyl Suppository 5 mg/10mg
120	Oral rehydration salts (ORS)
121	Zinc sulphate Dispersible Tablet 20 mg Zinc sulphate syrup
122	Dicyclomine Tablet 10 mg
123	Senna Powder (Herbal medicine)
124	Dioctyl sulfosuccinate sodium
125	Magnesium Hydroxide liquid
126	Sucralfate Tablet 10 mg, Sucralfate Oral Liquid 100 mg/ml
127	Hyoscine butylbromide Tablet 500 mg
	Medicines used in diabetes mellitus
128	Glimepiride Tablet 2 mg
129	Metformin Tablet 500 mg Metformin SR Tablet 500 mg
130	Insulin (Soluble) Injection 40 IU/ml
131	Premix Insulin 30:70 Injection (Regular:NPH) Injection 40 IU/ml
132	Glibenclamide Tablet 2.5 mg Glibenclamide Tablet 5 mg
133	Glucose Packet 75 mg for OGTT Test
	Thyroid and Anti-thyroid medicines
134	Levothyroxine Tablet 25 mcg Levothyroxine Tablet 50 mcg Levothyroxine Tablet 100 mcg
	Vaccines
135	As per current National programme guidelines
136	Rabies vaccine, Anti Rabies Serum
	Oxytocic & Abortificents Medicines
137	Misoprostol Tablet 200 mcg
138	Oxytocin Injection 5 IU/ml (Only where deliveries are conducted)
139	Nifedipine Tablet 10 mg
140	Methylergometrine Injection 0.2 mg/ml
	Psychotherapeutic Drugs
141	Alprazolam Tablet 0.25 mg*
142	Clonazepam Tablet 0.5 mg
143	Olanzapine Tablet 5 mg
	Medicines acting on the Respiratory tract
144	Budesonide Inhalation (MDI/DPI) 100 mcg/dose Budesonide Respirator solution for use in nebulizer 0.5 mg/ml
145	Salbutamol Tablet 2 mg Salbutamol Oral liquid 2 mg/5 ml Salbutamol Respirator solution for use in nebulizer 5 mg/ml
146	Montelukast Syrup Montelukast Tablet
147	Syrup Dextromethorphan
148	Syrup Bromhexine Hydrochloride
149	Syrup Pheniramine Maleate
150	Ipratropium Inhalation (MDI/DPI) 20 mcg/dose Ipratropium Respirator solution for use in nebulizer 250 mcg/ml.

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

Solutions correcting water, electrolyte disturbances and acid-base disturbances	
151	Ringer lactate Injection
152	Sodium chloride injection 0.9%
153	Pediatric solution like Isolyte P, N/2 & N/5
154	Potassium chloride Oral liquid 500 mg/5 ml
155	Dextrose 5% Dextrose 25%
Vitamins and minerals	
156	Ascorbic acid (Vitamin C) Tablet 100 mg
157	Calcium carbonate Tablet 500 mg
158	Cholecalciferol Tablet 60000 IU
159	Pyridoxine Tablet 25 mg Pyridoxine Tablet 50 mg Pyridoxine tablet 100 mg
160	Vitamin A Oral liquid 100000 IU/ml
161	B Complex Tablet B Complex Injection
Ophthalmological Medicines	
162	Lignocaine Eye drop 4%
163	Tropicamide Drops 1%
164	Ciprofloxacin Drops 0.3 %
165	Sodium cromoglycate 2% eye drop
166	Methylcellulose Eye drops
Contraceptives	
167	Ethinylestradiol (A) + Levonorgestrel Tablet 0.03 mg (A) + 0.15 mg (B)
168	Copper bearing intra-uterine device IUCD 380A & 375
169	Male Condom
170	Non- hormonal Ormeloxifene (30 mg Tablet)
171	Emergency Contraceptive Pill Levonorgestrel 1.5 mg
172	Medroxprogesterone Acetate Injection 150 mg

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

ANNEXURE 5: ESSENTIAL DRUG LIST- SUB-HEALTH CENTER- AYUSHMAN AAROGYA MANDIR

S. No.	Medicine Name
	Anesthetics Agent
1	Oxygen gas for inhalation
2	Lignocaine Topical form 5% (Plain Lignocaine Injection can be kept at SC if enough case load is there)
	Analgesics, antipyretics, non-steroidal anti-inflammatory medicines, medicines used to treat gout and disease modifying agents used in rheumatoid disorders
3	Aspirin (Acetylsalicylic acid) Tablet 75 mg (Not to be used in suspected dengue patients and other clinical conditions without prescription)
4	Diclofenac Tablet 50 mg Diclofenac Injection 25 mg/ml Diclofenac Gel 1%W/W
5	Ibuprofen Tablet 200 mg (Not to be used in suspected dengue patients and other clinical conditions without prescription)
6	Paracetamol tablet 250 mg, Paracetamol Syrup 125 mg/5 ml Paracetamol Syrup 250 mg/5 ml
	Anti-allergic and medicines used in anaphylaxis
7	Levocetirizine 5 mg Tablet Levocetirizine Oral Liquid
8	Hydrocortisone Succinate Injection 100 mg
9	Pheniramine Injection 22.75 mg/ml
10	Adrenaline Injection 1mg/ml (Should be part of all emergency drugs)
	Anti-dotes and other substances used in poisoning
11	Atropine Injection 1 mg/ml (Ampoules should be made available)
12	Activated Charcoal
	Anti-convulsant/ Anti-epileptic/ Anti-psychotic
13	Magnesium Sulfate Injection (50% solution), 2 ml ampoule
14	Diazepam Tablet 5 mg Diazepam Tablet 10 mg Diazepam rectal suppository* (Controlled medicine)
15	Midazolam Nasal Spray* (For emergency purpose)
16	Phenobarbitone Tablet 30 mg Phenobarbitone Tablet 60 mg Phenobarbitone Oral liquid 20 mg/5 ml
17	Phenytoin Tablet 50 mg Phenytoin Tablet 300 mg
18	Sodium valproate Tablet 200 mg Sodium valproate Tablet 500 mg Sodium valproate Syrup each 5 ml contains 200 mg
	Intestinal Anthelmintics
19	Albendazole Tablet 400 mg Albendazole Oral liquid 200 mg/5 ml
	Anti-filarial

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

20	Diethylcarbamazine Tablet 100 mg Diethylcarbamazine Oral liquid 120 mg/5 ml
	Anti-bacterial
21	Amoxicillin Capsule 250 mg, Amoxicillin Capsule 500 mg Amoxicillin Oral liquid 250 mg/5 ml Amoxicillin Dispersible Tablet 250 mg
22	Gentamicin Injection 10 mg/ml Gentamicin Injection 80 mg/m
23	Tab Co-trimoxazole [Sulphamethoxazol 80 mg +Trimethoprim 400 mg] Tab. 20 mg trimethoprim + 100 mg sulphamethoxazole Co-trimoxazole Oral Liquid [Sulphamethoxazole 200 mg + Trimethoprim 40 mg/5 ml]
24	Doxycycline Capsule 100 mg
25	Metronidazole Tablet 200 mg Metronidazole Tablet 400 mg
26	Norfloxacin tab/ oral Liquid
	Anti-leprosy medicines
27	As per Program Guidelines (Adults and Pediatrics)
	Anti-tuberculosis medicines
28	As per Program Guidelines (Adults and Pediatrics)
	Anti-fungal medicines
29	Clotrimazole Ointment Clotrimazole Cream 1% Clotrimazole Vaginal Tablet Clotrimazole Drops 1% Clotrimazole Oral Solution
30	Miconazole Ointment
31	Fluconazole 150 mg Tablet
	Anti-malarial medicines
32	As Per Program Guidelines (Adults and Pediatrics) As per NVBDCP Guideline
	Medicines used in Palliative care
33	Lactulose Oral liquid 10 g/15 ml
34	Povidone Iodine Lotion and Ointment
	Anti-anaemic medicines
35	Ferrous Salt (A) + Folic Acid (B): As per Anemia Mukt Bharat Abhiyan Children 06-59 months: Each ml of Iron and Folic Acid syrup containing 20 mg elemental Iron+ 100 mcg of Folic Acid. Children 05-9 years: Tablet 45 mg Elemental Iron (A) + 400 mcg (B)**[Pink Color]** Adolescent (10-19 Year): Tablet 60 mg Elemental Iron (A)+ 500 mcg (B) [Blue Color] Adult: Tablet 60 mg Elemental Iron (A)+ 500 mcg (B)[Red color]
36	Folic acid Tablet 5 mg Folic acid Tablet 400 mcg
37	Vitamin K Injection 1 mg/ml
38	Hydroxyurea Capsule 100 mg, 300mg, 500mg
	Cardiovascular medicines (Medicines used in angina)
39	Isosorbide-5- mononitrate Tablet 5 mg
40	Atenolol Tablet 50 mg
41	Metoprolol Tablet 25 mg Metoprolol SR Tablet 25 mg
42	Isosorbide dinitrate Tablet 5 mg (Sublingual)
	Anti-hypertensive medicines
43	Amlodipine Tablet 2.5 mg Amlodipine Tablet 5 mg
44	Enalapril Tablet 5 mg
45	Telmisartan Tablet 40 mg
46	Hydrochlorothiazide Tablet 12.5 mg Hydrochlorothiazide Tablet 25 mg
	Hypolipidemic medicines
47	Atorvastatin Tablet 10 mg
	Medicines used in Dementia

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

48	Alprazolam Tablet 0.25 mg Alprazolam Tablet 0.5 mg
	Dermatological medicines (Topical)
49	Silver sulphadiazine Cream 1%
50	Betamethasone Cream 0.05%
51	Calamine Lotion
52	Benzyl benzoate ointment/lotion
53	Mupirocin (anti -bacterial cream)
54	Potassium Permanganate 0.1%
55	Zinc Oxide Cream 10%
	Disinfectants and antiseptics
56	Ethyl alcohol (Denatured) Solution 70%
57	Hydrogen peroxide Solution 6%
58	Methylrosanilinium chloride (Gentian Violet)
59	Bleaching powder Containing not less than 30% w/w of available chlorine (as per I.P)
60	Gama Benzene Hexachloride
61	Framycetin sulphate (Ointment)
	Ear, nose and throat medicines
62	Ciprofloxacin Drops 0.3 % Ciprofloxacin Tablet 250 mg Ciprofloxacin Tablet 500 mg
63	Boro-Spirit ear drop
64	Ear wax solvent drops (combination of Benzocaine, Chlorbutol, Paradichlorobenzene and Turpentine Oil)
	Gastrointestinal medicines
65	Ranitidine Tablet 150 mg Ranitidine Injection
66	Omeprazole capsule 20 mg
67	Ondansetron Tablet 4 mg Ondansetron Oral liquid 2 mg/5 ml Ondansetron Injection 2 mg/ml
68	Ispaghula Granules/ Husk/ Powder (Herbal Medicine)
69	Oral rehydration salts (ORS)
70	Zinc sulphate Dispersible Tablet 20 mg Zinc Sulphate Syrup
71	Dicyclomine Tablet 10 mg Dicyclomine Injection
72	Dioctyl sulfosuccinate sodium
73	Magnesium Hydroxide liquid
74	Senna Powder (Herbal Medicine)
75	Domperidone Tablet Domperidone Syrup
	Contraceptives
76	Ethinylestradiol (A) + Levonorgestrel Tablet 0.03 mg (A) + 0.15 mg (B)
77	Copper bearing intra-uterine device IUCD 380 A & IUCD 375
78	Male Condom
79	Ormeloxifene Tablet 30mg
80	Emergency contraceptive Pill Levonorgestrel 1.5 mg
81	Medroxyprogesterone Acetate Injection 150 mg
82	FP Commodities: PTK
	Medicines used in Diabetes Mellitus
83	Glimepiride Tablet 2 mg
84	Metformin Tablet 500 mg Metformin SR Tablet 500 mg
85	Glibenclamide Tablet 2.5 mg/ Glibenclamide Tablet 5 mg
	Thyroid and Anti-thyroid medicines

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

86	Levothyroxine Tablet 25 mcg Levothyroxine Tablet 50 mcg Levothyroxine Tablet 100 mcg
	Vaccines
87	As per Current National Programme Guidelines
88	Rabies vaccine
	Oxytocics & Abortificent Medicine
89	Misoprostol Tablet 200 mcg (Should be use with caution)
	Medicines acting on the respiratory tract
90	Budesonide Respirator solution for use in nebulizer 0.5 mg/ml (Nebulizer Essential)
91	Salbutamol Tablet 2 mg Salbutamol Oral liquid 2 mg/5 ml Salbutamol Respirator solution for use in nebulizer 5mg/ml (Nebulizer Essential)
92	Normal Saline Drops
93	Dextromethorphan oral Syrup
94	Hyoscinebutylbromide Tablet 10 mg
	Solutions correcting water, electrolyte disturbances and acid-base disturbances
95	Ringer lactate Injection
96	Sodium chloride injection 0.9%
97	Dextrose 5% Dextrose 25%
	Vitamins and minerals
98	Ascorbic acid (Vitamin C) Tablet 100 mg
99	Calcium Carbonate Tablet 500 mg
100	Cholecalciferol Tablet 60000 IU
101	Pyridoxine Tablet 25 mg Pyridoxine Tablet 50 mg Pyridoxine Tablet 100 mg
102	Vitamin A Oral liquid 100000 IU/ml
103	B Complex Tablet
	Ophthalmological Medicines
104	Sodium Cromoglycate 2% Eye drop
105	Methylcellulose eye drops
	Diuretics
106	Furosemide Injection (Lasix) Furosemide Tablet 40 mg

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm

List of Contributors

Sr. No	Name	Designation	Organization
1.	Dr. S. K. Pambhoi	Director, Epidemiology Control and Director-SHIFW	Directorate of Health Services
2.	Dr. V. R Bhagat	Deputy Director	Directorate of Health Services
3.	Dr. Khemraj Sonwani		Directorate of Health Services
4.	Dr. Usha Joshi	Profession, Special Invitee	Sickle Cell Institute, Dr. B. R. Ambedkar Medical College, Raipur
5.	Dr. Dharmendra Gahwai	Deputy Director	Directorate of Health Services
6.	Dr. Shailendra Agrawal	State Program Officer	National Health Mission
7.	Dr. Ankit Sharma	Specialist	District Hospital
8.	Mr. Pankaj Upadhyay	General Manager- in-charge (Technical)	Chhattisgarh Medical Services Corporation
9.	Dr. Abhyuday Shakti Tiwari	O.S.D	National Health Mission
10.	Dr. Mo. Jawed Quraishi	State Planning Manager	National Health Mission
11.	Mr. Arun Lal Sahu	State Consultant-Procurement	National Health Mission
12.	Dr. Shashikant Swarnkar	In-charge- Deputy Director	Directorate of Health Services
13.	Mrs. Aakanksha Rana	Microbiologist, Central	Directorate of Health Services
14.	Mr. Varun Datt Jha	Consultant-Procurement, Central Store	National Health Mission
15.	Mrs. Sangita Patanwar	Consultant, Central Store	National Health Mission
16.	Mr. Mukeshkumar Kaushik	Programmer, Central Store	Directorate of Health Services
17.	Mr. David Kujur	Program Associate	Chhattisgarh Medical Services Corporation
18.	Dr. Tomeshkumar Harinkhede	State Technical Officer	PATH

File No. GENS-2101/4186/2025-HEALTH SECTION-2 (Computer No. 101127)
Generated from eOffice by Imamuddin, ASO(HEALTH)-7, ASSISTANT SECTION OFFICER(HEALTH), HEALTH & FAMILY WELFARE DEPARTMENT on 03/11/2025 03:53 pm